

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
2 June 2005 (02.06.2005)

PCT

(10) International Publication Number  
**WO 2005/049655 A1**

(51) International Patent Classification<sup>7</sup>: **C07K 16/28**,  
G01N 33/74, 33/53

(21) International Application Number:  
PCT/EP2004/013043

(22) International Filing Date:  
17 November 2004 (17.11.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
103 53 593.4 17 November 2003 (17.11.2003) DE

(71) Applicant (for all designated States except US):  
**KLINIKUM DER UNIVERSITÄT MÜNCHEN**  
[DE/DE]; Grosshadern-Innenstadt, Lindwurmstr. 2a,  
80337 München (DE).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **STRASBURGER**,  
Christian, J. [DE/DE]; Marchwartweg 8, 85635  
Höhenkirchen (DE). **BIDLINGMAIER**, Martin  
[DE/DE]; Schleissheimerstr. 68, 80797 München (DE).  
**WU, Zida** [DE/DE]; Strassbergerstr. 10, 80809 München  
(DE).

(74) Agents: **GRAF VON STOSCH**, Andreas et al.; Bosch,  
Graf von Stosch, Jehle, Patentanwalts-gesellschaft MBH,  
Flüggelstr. 13, 80639 München (DE).

(81) Designated States (unless otherwise indicated, for every  
kind of national protection available): AE, AG, AL, AM,  
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,  
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,  
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,  
KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,  
MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG,  
PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,  
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM,  
ZW.

(84) Designated States (unless otherwise indicated, for every  
kind of regional protection available): ARIPO (BW, GH,  
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,  
ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),  
European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI,  
FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE,  
SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,  
GW, ML, MR, NE, SN, TD, TG).

**Published:**

- with international search report
- before the expiration of the time limit for amending the  
claims and to be republished in the event of receipt of  
amendments

For two-letter codes and other abbreviations, refer to the "Guid-  
ance Notes on Codes and Abbreviations" appearing at the begin-  
ning of each regular issue of the PCT Gazette.

(54) Title: LEPTIN ANTAGONIST AND METHOD FOR QUANTITATIVE MEASUREMENT OF LEPTIN

(57) Abstract: This invention relates to specific antibodies or fusion proteins, in particular a specific antibody A or a fusion protein directed to a leptin receptor (leptin-R) or a leptin-binding protein (leptin-BP), as well as to the use of these antibodies or fusion proteins for quantitative analysis, for therapeutic purposes and for the preparation of therapeutic drugs. Furthermore, the invention relates to a method for quantitative determination of leptin in the sample of solubilized or suspended leptin-binding proteins by using specific antibodies or fusion proteins according to the invention, as well as to diagnostic agents and (diagnostic) kits containing this antibody or fusion protein.



**WO 2005/049655 A1**

5

10

15

Leptin antagonist and method for quantitative measurement of leptin

20

This invention relates to specific antibodies or fusion proteins, in particular a specific antibody A or a fusion protein directed to a leptin receptor (leptin-R) or a leptin-binding protein (leptin-BP), as well as to the use of these antibodies or fusion proteins for quantitative analysis, for therapeutic purposes and for the preparation of therapeutic drugs. Furthermore, the invention relates to a method for quantitative determination of leptin in the sample of solubilized or suspended leptin-binding proteins by using specific antibodies or fusion proteins according to the invention, as well as to diagnostic agents and (diagnostic) kits containing this antibody or fusion protein.

30

Leptin (derived of the Greek term leptos = thin) is a protein hormone, that is primarily segregated by the fat cells (adipocytes). In 1994, leptin (Zhang et al. (1994) Na-

ture 372, 425) was discovered as genetic product of the obesity gene (*ob* gene) with a molecular weight of approx. 16 kDa, formed by 146 amino acids. It plays an important role in energy metabolism (Friedman et al., (1998) Nature 395, 763 – 770). Apart from its relevance for energy metabolism, its contribution to the modulation of immunocompetent cells (Lord et al., (1998) Nature 394, 6696) or haemopoietic cells (Sierra-Honigsmann et al., (1998) Science 281, 1683-1686) has been described in the meantime as well as a permissive function in the induction of puberty (Quinton et al., (1999) J Clin Endocrinol Metab 84(7), 2336-41). Leptin has also been strongly associated with diabetes and chronic heart failure (CHF) (see E.M. El-Bindary and A.Z. Darwish, Volume 7, Nos 4/5, July - September 2001, 697- 706).

In mice (*ob/ob* mouse), the lack of the leptin gene (*ob/ob* mouse) leads to massive overweight (adipositas). Due to the fact, that administration of leptin to *ob/ob* mice induces reduced food uptake and finally weight reduction, leptin was attributed some importance as an appetite suppressant. Anyhow, the situation is far more complex.

The effect of leptin is mediated via the leptin receptor (leptin-R) (Tartaglia et al., (1995) Cell 83(7), 1263-71), thus activating intracellular signal cascades. The leptin receptor pertains to the so-called class I of the cytokine receptor superfamily. In many receptors of this family, an extra-cellular portion of the leptin receptors circulates as leptin-binding protein in the blood, and this is also the case for the leptin receptor.

Defects of the leptin receptor were identified as a cause of overweight problems in human beings (Clement et al., (1998) Nature 392, 398 – 401). Conversely, patients suffering from anorexia nervosa (diminished appetite) seemingly have increased leptin levels in relation to their reduced fat mass. Therefore, determination of leptin concentration in blood or in serum samples is an important diagnostic tool for clarification of the underlying cause of eating disorders or extreme obesity.

As mentioned above, El-Bindary and Darwish (2001) have strongly associated leptin with diabetes and chronic heart failure (CHF). El-Bindary and Darwish (2001) investigated the interaction of TNF- $\alpha$ , leptin levels and insulin in patients suffering from CHF. CHF constitutes a complex syndrome associated with disturbance in several metabolic and endocrine functions. There is accumulated evidence that weight loss and cachexia seen in advanced stages of CHF constitute a poor prognosis in patients suffering therefrom. In particular, an increased plasma leptin level is assumed to be implicated in the wasting associated with late stage heart failure. Additionally, chronic heart failure is characterized by a hyperinsulinaemic state (Swan et al., Journal of the American College of Cardiology, 1997, 30:527–32), in which there is striking loss of both muscle and adipose tissue leading to overt cardiac cachexia in these patients (see Cleland and Clark, European heart journal, 1998, 19:1421–2). Recent attention has therefore been focused on cytokine activity in CHF. According to El-Bindary and Darwish (2001), there is a significant elevation of TNF- $\alpha$  in late stage CHF. Apparently, the level of circulating TNF- $\alpha$  is elevated in patients with advanced CHF. Assumably, TNF- $\alpha$  may contribute to the progression of the cardiac decompensation that occurs in advanced cases of CHF. The results also reveal a correlation between TNF- $\alpha$  and plasma leptin concentration. TNF- $\alpha$  may act directly on adipocytes to increase the production of the lipostatic factor leptin, wherein the level of serum leptin appears to be under control of TNF- $\alpha$ . Hence, there is a significant elevation of the insulin level and a correlation with TNF- $\alpha$  in late stage CHF. El-Bindary and Darwish (2001) also found evidence for a positive correlation between plasma leptin and insulin level in late-stage disease. Increased plasma leptin and associated increase in insulin were considered to be another cachexia causing factor. Increase in plasma TNF- $\alpha$ , leptin and insulin levels, and positive correlation between them in late stage heart failure may constitute one of many vicious circles of advanced stage CHF.

Since disorders of energy metabolism, in particular eating disorders, such as anorexia nervosa (diminished appetite), are observed more frequently, the identification of effective leptin-antagonists that may reduce, inhibit or even block the function of leptin, is of major interest and economic significance.

5

Therefore, it is a first object of the present invention to provide an antagonist of leptin-R and leptin-BP. Such an antagonist may be suitable in the treatment of diseases and/or symptoms associated with excessive leptin levels, such as diabetes, cachexia, obesity, chronic heart failure (CHF), etc., as well in the development and  
10 provision of a medicament and/or therapies for such diseases.

By using suitable leptin-antagonists (as mentioned above), regulatory mechanisms and specific effects of leptin are amenable to examination *in vitro* by selective inhibition of the leptin receptor and/or displacement of leptin from leptin-binding proteins.  
15

In the light of the above, the quantitative determination of leptin in a sample and in particular in physiological body liquids – such as e.g. blood - is a prerequisite for therapeutic treatment and an important diagnostic tool. Many e.g. hormones or  
20 other messenger substances (ligands), bind specifically to their membrane receptors, the extracellular domain(s) of which is (are) frequently solubilized or suspended in the liquid. Thereby, a complex composed of ligands to be determined, e.g. leptin (ligand) and the leptin-binding protein, is formed, which influences (reduces) the level of free ligand in the sample. In order to avoid that problem, a labeled ligand is  
25 used and added to the sample. Nevertheless, the binding protein may bind to the labeled ligand in the solution and thus, the ligand is not detectable in the sample. Therefore, the binding protein interferes with quantitative ligand measurement and diagnostics.

Generally, so-called immunoassays are used for the analysis of the leptin concentration. They are based on the principle of an interaction of specific antibodies with an analyte. Alternatively, competitive assays are used (such as the radioimmunoassay, RIA), in which labeled leptin competes with the leptin present in the sample for the binding site on an antibody, thus generating a signal being inversely proportional to the concentration of the analyte to be determined. However, nowadays, sandwich-immunoassays are used most frequently, in which an immobilized specific antibody binds the analyte ("capturing antibody"), and subsequently, a second, labeled antibody, directed to a different epitope of the analyte, binds the analyte, which is then immobilized. This generates a signal, that is proportional to the amount of the bound analyte. The best-known example of this measurement method is the "enzyme linked immuno sorbent assay" (ELISA) with a colorimetric endpoint. Other possibilities for the generation of a signal are radioactivity, chemoluminescence or (time resolved) fluorescence.

15

All assay methods mentioned above are based on the principle of the highly affine, specific binding between an antibody directed to a e.g. hormone ligand – leptin, in this case - and the hormone ligand in the sample to be analyzed.

20

The main source of interference in the measurement of leptin in serum or blood is the presence of a highly affine leptin-binding protein, namely the soluble extracellular portion of the leptin receptor in human serum. The effect of this leptin-binding protein on the measurement result may cause erroneously high or erroneously low values, always depending on the type of assay used (competitive assay or sandwich-assay). In the competitive assay, on the one hand, the labeled leptin (as a so-called "tracer") may be bound by the leptin-binding protein, thus being removed from solution, resulting in erroneously high concentrations. On the other hand, the leptin-binding protein may also block sterically the interaction of the specific antibody with the leptin molecules from a serum sample and thus may also cause erroneously low concentrations in the competitive assay. In contrast, this steric obstruc-

30

tion of the interaction between antibody and hormone generally provokes erroneously low results in the sandwich-immunoassay, since less hormone or less detection antibody will be bound. The error in the measurement results caused by this interference will become particularly relevant in the presence of certain physiological or pathological conditions that are associated with a change of leptin concentration in the blood.

Since Leptin-BP binds leptin in a sample and thus reduces the amount of free leptin in the sample, no unequivocal determination of physiological leptin concentrations can be obtained. Thus, due to the presence of soluble leptin-binding proteins, all experimental data for body fluid leptin levels are biased by interferences between leptin and leptin-binding protein.

In order to develop a standardizable diagnostic method or a therapeutic treatment for diseases such as obesity, diabetes and/or chronic heart failure (CHF), etc., there is a need for selective, specific and effective substances or molecules that bind to a leptin receptor and/or a leptin-binding protein. To date, only few substances or molecules are known, which selectively, specifically and effectively bind to a leptin receptor and/or a leptin-binding protein. Selectivity and specificity are prerequisites for quantitative and qualitative determination. Gonzales et al. (Gonzales et al., (2003) Mol Hum Reprod 9(3), 151-8) for instance report on polyclonal antibodies, that seem to inhibit leptin effects to a certain extent. However, such polyclonal antibodies cannot be reproduced, they cannot be humanized and are available only in limited amounts.

On the one hand, alternative solutions to avoid measurement inaccuracies relate to methodic extraction methods, that are carried out before the actual measurement method itself, in order to eliminate, e.g. the leptin-binding proteins. Anyhow, this implies significantly increased efforts as to the methods used and may simultaneously lead to misleading results. Altogether, to date there is no satisfactory state-of-

the-art-solution to the difficulties of eliminating soluble leptin-binding proteins in samples to be analyzed.

Therefore, it is a second object of the invention to provide a method to obtain reliable results of the ligand level, e.g. leptin, of a sample containing leptin-binding protein(s) or leptin receptors with its /their ligand(s).

This object is solved by the present invention, which may render test methods, in particular assays for (body liquid) leptin determination, less susceptible to falsifying interference by leptin-binding protein. Such method may i.a. be suitable for the diagnosis of diseases and/or symptoms associated with excessive leptin levels, such as diabetes, cachexia, obesity, chronic heart failure (CHF), etc..

The inventors of the present invention succeeded in identifying and providing a molecule - in form of an antibody - that in essence specifically prevents the binding of leptin to a leptin receptor (leptin-R) and displaces leptin, which is bound to a leptin-binding protein, from this leptin-binding protein (leptin-BP).

Therefore, the invention provides an antibody A against a leptin receptor (leptin-R) and/or a leptin-binding protein (leptin-BP), characterized in that it fundamentally reduces and, preferably, prevents the interaction of the leptin receptor and/or of the leptin-binding protein with its ligand, i.e. leptin.

A "leptin-binding protein" or "binding protein" (both termed leptin-BP) or "leptin receptor" (leptin-R) within the meaning of this invention comprises all proteins, that can bind with high affinity (specifically) to leptin to be determined in a sample. Leptin-binding protein is usually soluble or be present in the sample as a suspension. Leptin-binding protein is usually found in body liquid samples, e.g. serum, as the extra-cellular portion of the leptin receptor. Anyhow, it may also be located close to the cell membrane. Examples for human sequences of such leptin-binding



proteins or binding proteins or leptin receptors are the sequences O95214, P48357 and O15243 (source: Swiss-Prot/TrEMBL). Preferably they are leptin-binding proteins or binding proteins or leptin receptors of human origin, however, this invention also comprises corresponding proteins of all other vertebrates, in particular mammals, such as rat, mouse, pig, horse, cattle. Examples for such sequences are O02671, Q9MYL0, P48356, Q62959, O89013, Q9JLS8 (source: Swiss-Prot/TrEMBL). Preferably, the leptin-binding protein is a physiological leptin-binding protein, solubilized or suspended in liquid, preferably body liquid.

- 10 According to the present application, the term "antibody" comprises monoclonal antibodies, polyclonal antibodies, particularly polyclonal monospecific antibodies (i.e. antibodies with different variable regions, which however all recognize a specific epitope), as well as chimeric antibodies, (anti-)anti-idiotypic antibodies (directed to the inventive antibodies), and genetically manipulated antibodies that are
- 15 all present in bound or soluble form and may – if appropriate - be labeled by "markers" (for example fluorescence marker, gold marker, coupled enzymes). The term "antibody" in the meaning of the present invention typically refers to full-length antibodies of the afore mentioned antibodies. A "full-length" (monoclonal) antibody in the meaning of the present application may be any of the above mentioned inventive antibodies in its full-length form. A full-length antibody of the present invention typically comprises both the domains of the heavy chain and the light chain. The heavy chain of the inventive antibody includes domains  $C_H1$ ,  $C_H2$  or  $C_H3$  of the constant region and the variable heavy ( $V_H$ ) immunoglobulin domain. The , the light chain of the inventive antibody includes the variable light immunoglobulin
- 20 domain ( $V_L$ ) and the constant light immunoglobulin domain ( $C_L$ ). Antibodies, not containing all the aforementioned domains or regions of an antibody are fragments of antibodies within the meaning of the present invention. Fragments of antibodies according to the present invention are further defined below.
- 25

Apart from the inventive antibodies as such, antibodies according to this invention may also be provided as portion of a fusion protein containing other (protein)-constituents. Fusion proteins containing an inventive antibody or its fragment thereof are defined below. All of the aforementioned embodiments fall under the scope of an inventive antibody A.

Antibodies according to the present invention may pertain to one of the following immune globulin classes: IgG, IgM, IgE, IgA, GILD and, if applicable, a subclass of the aforementioned classes, such as the subclasses of the IgG or their mixtures. IgG and its subclasses such as IgG1, IgG2, IgG2a, IgG2b, IgG3 or IgGM are preferred. The IgG subtypes IgG1/k or IgG2b/k are specifically preferred.

Antibodies in the sense of this invention are furthermore proteins or possibly other structures produced by vertebrates or by artificial production methods, that bind with high affinity to a determined surface conformation (epitope) of an antigen, i.e. of another molecule, preferably mono- or polyclonal (partial) structures of the above mentioned immune globulins or also polyclonal monospecific antibodies. Typically, such antibodies contain at least the variable part of immune globulins, and, as the case may be, at least one domain of the constant domain of immune globulins, too.

"Polyclonal antibodies" in the meaning of the present application are typically heterogeneous mixtures of antibody molecules, produced from animal serums, that had been immunized with an appropriate antigen, i.e. a ligand of the antibody A of the present invention, preferably with leptin-BP and/or leptin-R.

A "monoclonal antibody" contains a fundamentally homogeneous population of antibodies, that are directed specifically to antigens, and fundamentally, antibodies show similar epitope-binding sites here. The different antibody variants with monospecificity may belong to the immune globulin classes described above. They may also be mixtures of different major primary classes or subclasses, preferentially, they

consist of a homogenous mixture of IgG-antibodies. This homogeneity may also be achieved by an additional purification step (immuno-precipitation, chromatography, for example by using antibodies directed to IgG).

- 5 Monoclonal antibodies may also be obtained by using methods known in the state-of-the-art (e.g. . Köhler und Milstein, Nature, 256, 495-397, (1975); US-Patent 4,376,110; Ausübel et al., Harlow und Lane "Antikörper": Laboratory Manual, Cold Spring, Harbor Laboratory (1988); Ausubel et al., (eds), 1998, Current Protocols in Molecular Biology, John Wiley & Sons, New York)). The aforementioned references
- 10 are included herein in their entirety. "Monoclonal" is intended to mean in particular the product of an artificial construct, in which an antibody-producing cell (B-cell) is fused with an immortalized cancer cell (hybridom), creating a hybridoma cell. Specific antibodies, that are all exclusively directed to one epitope, are produced by this cell. A hybridoma-cell clone, producing monoclonal antibodies according to
- 15 the present invention, is cultured *in vitro*.

"Genetically manipulated antibodies" according to the present invention may also be produced using the methods described in the aforementioned publications.

- 20 "Chimeric antibodies" according to the present invention are molecules, that contain different constituents, which are derived from different animal species (e.g. antibodies, showing a variable region, that is derived from a monoclonal mouse antibody and a constant region of a human immunoglobulin). Chimeric antibodies are preferably used on the one hand for the reduction of immunogenicity, if adminis-
- 25 tered, and on the other hand for the increase of yield, e.g., murine monoclonal antibodies yield higher rates of production from hybridoma cell lines, however, they are also associated with a higher immunogenicity in humans. Therefore, human/murine chimeric antibodies are preferably used. Chimeric antibodies and methods for their production are known state-of-the-art methods. (Cabilly et al., Proc. Natl. Sci. USA
- 30 81: 3273-3277 (1984); Morrison et al. Proc. Natl. Acad. Sci USA 81:6851-6855

(1984); Boulianne et al. *Nature* 312 643-646 (1984); Cabilly et al., EP-A-125023; Neuberger et al., *Nature* 314: 268-270 (1985); Taniguchi et al., EP-A-171496; Mor-  
rion et al., EP-A-173494; Neuberger et al., WO 86/01533; Kudo et al., EP-A-  
184187; Sahagan et al., *J. Immunol.* 137: 1066-1074 (1986); Robinson et al., WO  
5 87/02671; Liu et al., *Proc. Natl. Acad. Sci USA* 84:3439-3443 (1987); Sun et al.,  
*Proc. Natl. Acad. Sci USA* 84:214218 (1987); Better et al., *Science* 240: 1041-1043  
(1988) und Harlow und Lane, *Antikörper: A Laboratory Manual*, as quoted above).  
These references are also included in the present invention, as if disclosed in their  
entirety.

10

An "anti-idiotypic antibody" according to the present invention is an antibody that  
recognizes a determinant, which is generally associated with the antigen binding  
site of an antibody according to the present invention, e.g. an anti-leptin-binding  
protein antibody. An anti-idiotypic antibody can be produced through immuniza-  
15 tion of an animal of the same species and the same genetic type (e.g. a mice strain)  
as a point of origin for a monoclonal antibody, against which an anti-idiotypic anti-  
body according to this invention is targeted. The immunized animal will recognize  
the idiotypic determinants of the immunizing antibody through the production of an  
antibody, that is directed to the idiotypic determinants (namely against an anti-  
20 idiotypic antibody according to the present invention), (U.S. 4,699,880). An anti-  
idiotypic antibody according to the present invention may also be used as an im-  
munogen, in order to provoke an immune response in another animal and to induce  
the production of a so-called anti-anti-idiotypic antibody there. The anti-anti-  
idiotypic antibody may be, but does not have to be, identical to the original mono-  
25 clonal antibody with reference to the design of its epitope, that had caused the anti-  
idiotypic reaction. This allows the identification of other clones, that express anti-  
bodies of identical specificity, with the use of an antibody directed to idiotypic de-  
terminants of a monoclonal antibody.

In order to induce binding of anti-idiotypic antibodies in the respective animals, such as e.g. the BALB/c mouse, monoclonal antibodies, directed to a physiological binding protein of a physiological ligand, e.g. leptin-binding protein, solubilized or suspended in body liquids, can be used. Cells taken from the spleen of such an immunized mouse can be used to produce anti-idiotypic hybridoma-cell lines, that secrete anti-idiotypic monoclonal antibodies. Furthermore, anti-idiotypic monoclonal antibodies may also be coupled to a medium (KLH, "keyhole limpet hemocyanin") and subsequently be used for further immunization of BALB/c-mice. The sera of these mice contain anti-anti-idiotypic antibodies, that exhibit the binding properties of the original monoclonal antibodies and that are specific for a physiologic binding protein solubilized or suspended in body liquids of a physiologic ligand (ref. preferred examples below). Therefore, the anti-idiotypic monoclonal antibodies have their own idiotypic epitopes or "idiotopes", characterized by a similar structure as the structure of the epitope to be examined

In a preferred embodiment of the invention, the inventive antibody is directed to the extra-cellular domain of a leptin receptor, in particular to a leptin-binding protein. In a more preferred embodiment, the antibody A according to the present invention is directed to the leptin-binding site on a leptin-binding protein, to which the ligand (e.g. leptin) binds. Furthermore, the ligand is preferably leptin. In this context, the term "antibody directed to the leptin-binding site on a leptin-binding protein", means that the antibody as a binding epitope binds specifically and with high affinity to the binding site of the ligand (e.g. leptin) on the leptin-binding protein.

Furthermore, an antibody of the present invention may also be bispecific, that is to say, it may also recognize different epitopes with its two paratopes, preferably two different epitopes of the same protein or peptide (see above). Eventually, both paratopes may be structural different, however, they may still bind the same epitope or at least overlapping areas of these epitopes.

According to another embodiment, the antibody A according to the present invention is humanized and directed to a human leptin receptor or a human leptin-binding protein. Humanization of antibodies is known in the prior art can be performed by a large variety of standard methods. Therefore, human or humanized antibodies are also understood as antibodies according to the present invention.

"Fragments" of an antibody according to the present application are also encompassed by the present invention. A "fragment of an antibody according to the present application" typically may comprise any fragment of an antibody of the present application, either fragments of a polyclonal or monoclonal antibody. A fragment of an inventive antibody thus may comprise e. g. the constant regions of the heavy chain of the inventive antibody, e.g.  $C_{H1}$ ,  $C_{H2}$  or  $C_{H3}$ , the variable heavy ( $V_H$ ) immunoglobulin domain, the variable light immunoglobulin domain ( $V_L$ ), or the constant light immunoglobulin domain ( $C_L$ ). The constant heavy immunoglobulin domain is typically an  $F_c$  fragment comprising the  $C_{H3}$  domain and/or the  $C_{H2}$  and/or the  $C_{H1}$  domain. The variable light immunoglobulin domain is preferably an  $F_{ab}$  fragment comprising the  $V_L$  domain. Also encompassed are all shortened or modified antibody fragments presenting one or two binding sites complementary to the antigen, such as antibody parts with a binding site corresponding to the antibody, composed of a light and a heavy chain, such as  $F_v$ ,  $F_{ab}$  or  $F_{(ab')_2}$ -fragments or single-chain antibody fragments ( $scF_v$ ). Shortened double strand fragments, such as  $F_v$ ,  $F_{ab}$  or  $F_{(ab')_2}$  are preferred.  $F_{ab}$  and  $F_{(ab')_2}$ -fragments have no  $F_c$ -fragment, which would be present for instance in an intact antibody, therefore, they may be transported faster in the blood circulation and show comparably less non-specific tissue binding than intact antibodies. In this context, it is stressed, that  $F_{ab}$  and  $F_{(ab')_2}$  fragments of antibodies according to the present invention can be used in an inventive method in the sense of the invention presented. Such fragments are typically produced by proteolytic cleavage, using enzymes, such as e.g. papain (for the production of  $F_{ab}$ -fragments) or pepsin (for the production of  $F_{(ab')_2}$  fragments), or by chemical oxidation or by genetic manipulation of the antibody genes.

Furthermore, fragments of the antibodies of the present invention are typically functionally homolog to the antibodies of the present invention.

- 5 “Functionally homolog” in the meaning of the present invention means that a fragment, a variant, etc. of an antibody of the present invention preferably recognizes specifically a sequence of a leptin-R or a leptin-BP. More preferably, a functional homolog of an antibody of the present invention recognizes specifically an epitope of a leptin-R or a leptin-BP. Even more preferably, the functional homolog of an antibody of the present invention recognizes specifically the leptin binding site of leptin-R or leptin-BP. A functional homolog of an antibody of the present invention means that this homolog is capable of displacing Leptin from its binding to leptin-R or leptin-BP.
- 10
- 15 A “functional homolog” of an antibody of the present invention is also understood to include antibodies with increased or lowered affinity to leptin-R or leptin-BP and/or increased lowered capability of displacing Leptin from its binding to leptin-R or leptin-BP as compared with a full-length antibody of the present invention. Such a high affinity antibody of the present invention preferably comprises or consists of an amino acid sequence, being encoded by SEQ ID NO: 5 or comprises the amino acid sequence SEQ ID NO: 6. Such antibodies with a modulated activity may exhibit different biological properties. Furthermore, a person skilled in the art may select an antibody with a specific affinity as necessary in the respective case.
- 20
- 25 In a more preferred embodiment a fragment of an antibody of the present invention comprises or consists of a protein sequence encoded by a nucleic acid sequence selected from SEQ ID NOs: 2, 4, 5, or 7. Alternatively, such a fragment comprises or consists of a protein sequence selected from SEQ ID NOs: 1, 2, 3, 4, 6 or 8.

In a specific embodiment, the antibody A according to the present invention is the antibody ZMC2. ZMC2 is a monoclonal antibody, directed to the binding site of human leptin on the human leptin-binding protein and in the framework of the invention it had been optimized for the solution of this task. The monoclonal antibody  
5 ZMC2 has been deposited in viable form by the applicant with entry dated September 25, 2003 under deposit number DSM ACC 2618 along with the reference "ZMC2", assigned by the depositor, according to the stipulations of the Budapest Treaty at DSMZ (Deutsche Sammlung für Mikroorganismen und Zellkulturen GmbH) in Braunschweig.

10

"Variants" of any of the above mentioned inventive antibodies, particularly variants of the inventive antibody ZMC2, are also contemplated by the present invention. A variant of an antibody, particularly a variant of ZMC2, in the meaning of the present invention typically comprises a sequence, wherein at least one, two or more amino  
15 acids, preferably 1-5, 1-10, 1-15 or 1-20 amino acids, of the entire amino acid sequence of said antibody are altered, i.e. deleted, substituted or added with respect to the amino acid sequence of the full-length antibody of the present invention, e.g. ZMC2. Variants of antibodies of the present invention, particularly variants of ZMC2, are preferably functionally homolog to the full-length non-altered antibodies  
20 of the present invention, particularly to ZMC2.

"Fusion proteins" are also provided by the present invention. A "fusion protein" according to the present invention typically comprises a portion I and a portion II, wherein portion I may be any antibody or antibody fragment according to the present invention fused to other (protein)-constituents as portion II. Typically, portion I  
25 of such a fusion protein represents a full-length antibody. Alternatively, portion I of such a fusion protein may comprise any of the above mentioned fragments of an inventive antibody, preferably  $V_H$  or  $V_L$ . (Protein)-constituents as portion II of a fusion protein of the present invention typically comprise any antibody or antibody  
30 fragment according to the present invention, or any peptide or protein, forming in-



teractions with other proteins, e.g. ligands of leptin-R and/or leptin BP, preferably leptin or fragments or variants of leptin. It is preferred to use components as portion II, which specifically recognize cells to be targeted by the inventive fusion protein. Cells to be targeted are typically adipocytes, connective tissue cells and other leptin binding cells. A fragment of a leptin as used in the inventive fusion protein is preferably a shortened leptin molecule, still capable of binding to the leptin binding site of leptin-R or leptin-BP. A variant of a leptin as used in the inventive fusion protein is preferably a full-length leptin molecule, comprising one or more amino acid substitutions, but still being capable of binding to the leptin binding site of leptin-R or leptin-BP. Therefore, the inventive fusion protein is preferably "bispecific", i.e. it is capable of binding two target molecules, whereby portion I is specific for target molecule I and portion II is specific for target molecule II. If the inventive fusion protein comprises e.g. leptin as portion II of the fusion protein, it may act as a so called "super-antagonist". This is due to the fact that leptin binds as a dimer to. Consequently, a fusion protein consisting of an inventive antibody (or a fragment thereof, both acting as an antagonist) as portion I and leptin (or a fragment thereof, or a high affinity leptin molecule) as portion II enable a fusion protein to bind with a higher strength and a better specificity to leptin-R or leptin-BP and to displace leptin from its binding to leptin-R or leptin-BP even more efficiently than an inventive antibody as such.

Inventive antibodies as constituents of fusion proteins (as portion I or II) are typically provided by using the methods of enzymatic cleavage, protein-synthesis or by using those recombinant methods, as known by the expert in biochemistry or molecular biology.

The inventive fusion protein may comprise an inventive antibody (or a fragment thereof, both acting as an antagonist) as portion I and a second antibody as portion II. Alternatively, the inventive fusion protein may comprise an inventive antibody (or a fragment thereof, both acting as an antagonist) as portion I and a scFv-fragment

of the inventive antibody as portion II. Such a fusion protein allows to potentially target the antibody to a specific cell type e.g. to obtain bispecific fusion proteins thereby. Preferably, the bispecific fusion protein is directed to a leptin receptor and/or a leptin-binding protein as first specificity and to a cell surface protein as second specificity of portion II. The inventive antibody, such as ZMC2, may be linked to an antibody, such as CD4-F<sub>ab</sub>, directed to e.g. CD4 (or CD1, 2, 3, 4, 5, 6, 7, 8, 9, 10, CD 25, CD44, etc.). E.g. antibodies recognizing cell surface proteins of specific immune cells allow an inventive fusion protein to specifically bind to immune cells. In this case the affinity of both F<sub>ab</sub>'s could be altered to get a preferential effect. For example, a high affinity CD4-F<sub>ab</sub> as a bispecific antibody could then target CD4 cells.

Portions I and II of the inventive fusion protein optionally may be linked by a linker sequence. Preferably, the linker comprises a length of about 5 to 40 amino acids, more preferably between 5 and 30 amino acids and most preferably between 5 and 20 amino acids. Also preferably, the linker comprises a sequence containing at least 50% glycine residues, preferably at least 60 %, more preferably at least 70% and most preferably at least 80%.

In a specifically preferred embodiment, the fusion protein of the present invention comprises or consists of a protein sequence encoded by the nucleic acid sequence SEQ ID NO: 7 or of the protein sequence SEQ ID NO: 8.

Furthermore, an inventive antibody, a fragment thereof or a fusion protein according to the present invention, may have further covalently (or not covalently) coupled molecules or groups, for example a fluorescence marker or other markers, for example a gold label, or specific epitopes, that can be recognized by third molecules.

The subject matter of the invention disclosed herein are also mixtures (compositions) of the inventive antibodies in the above sense, for instance mixtures of mono-

clonal antibodies or mixtures of monoclonal antibodies with antibody fragments, mixtures of anti-idiotypic antibodies etc..

Another embodiment of the present invention is a method for preferably quantitatively determining a ligand in a sample containing the ligand of a binding protein, e.g. in solubilized or suspended form, wherein at least one antibody A or an inventive fusion protein according to the present invention is added to the sample to be determined (step a). This inventive method (step a) may be followed by a second step (step b) determining the ligand concentration in the sample.

An "antibody A" as used for the present inventive method is defined as given above.

According to the present inventive method, the antibody A or an inventive fusion protein may be added to the sample before or during, preferably before, quantitative determination of the ligand concentration, e.g. leptin, in the sample, and/or may be incubated together with the sample.

An antibody A according to the present invention, that binds exactly and with high affinity to the site of the leptin-binding proteins, to which the ligand binds, is especially preferred. Due to the binding of the inventive molecule, e.g. an antibody A or an inventive fusion protein, a displacement of the ligand (leptin) from the leptin-binding protein occurs, preventing simultaneously binding of the ligand. This displacement will obviously be dependent on the increase of the amount of antibody A or inventive fusion protein added. Thus, a major excess of antibody A or inventive fusion protein over the molar leptin-binding protein concentration is mostly favourable for carrying out the inventive method.

The ligand (e.g. leptin) is "released" through the displacement and can subsequently be measured quantitatively without steric inhibition due to the binding activity of the leptin-binding protein.

A "ligand" as used in an inventive method typically comprises all compounds, that bind with high affinity to a leptin receptor and/or a leptin-binding protein and allow a measurement of their concentration in specific assays, and all compounds that are also determined, for instance for medical purposes. E.g. messenger substances, such as hormones, transmitters, for instance neurotransmitters, extra-cellular signal peptides or proteins, cytokines, chemokines, lymphokines etc. are compounds in the meaning of the present invention. Leptin is a preferable ligand of the invention. A ligand in the meaning of the present invention may also be a "physiological ligand". Such a "physiological ligand" is typically a ligand in the above sense, which is found in the body of a vertebrate, in particular in a body liquid, without being added exogenously. Correspondingly, this is also applicable for the physiological leptin-binding protein, where this is also the leptin-binding protein of the physiological ligand, naturally to be found under physiological conditions.

A "sample" in the sense of this invention is typically to be understood as any type of solution to be tested, in particular solutions of medically relevant substances, such as e.g. blood, lymph, serum, urine, liquor, also in a processed form, prepared for the sample handling. Likewise, it is preferable, if the sample to be determined in the inventive method contains liquid, preferably body liquid, more preferably human body liquid, in particular blood or human blood.

A "body liquid" is to be understood as each liquid obtained from the body of a vertebrate, in particular a mammal, in particular of a human being. In the case of human beings, this would for instance be blood, urine or lymph, but also cytosolic preparations from human cells.

The term "in solubilized or suspended form" in the meaning of the present invention is to be understood as any form of solution of the leptin-binding proteins or of the ligand in the broader sense in the solution medium. This also includes situations, in

which for instance the leptin-binding protein is about to precipitate or has already precipitated, as long as it is still a constituent of the solution.

“Quantitative determination” in the context of the inventive method is to be understood as any method known by a skilled person for determining the amount of an analyte solved in a sample. This includes explicitly, e.g. quantification by using chromatographic methods with a concurrent standard, in particular a quantification by using the highly affine interaction between antibody and ligand (antigen) via competitive assays or binding assays, such as e.g. a sandwich assay, also in the ELISA format. A specific advantage of this invention is the fact that adding a specific antagonistic antibody or an inventive fusion protein to a sample as disclosed herein can be combined with practically all known - in particular commercially available - test kits or test systems for quantitative analysis of the respective analyte (ligand) without any efforts.

In the inventive method preferably the antibody A or an inventive fusion protein is added prior to or during, preferably prior to the quantitative determination and/or is incubated with the sample.

The sample to be tested is typically incubated together with antibody A or an inventive fusion protein. The term “incubation”, as used herein is to be understood as a reaction condition, in which the reaction partners, in other words antibody A or an inventive fusion protein and leptin-binding protein are allowed to react with each other. Typically, antibody A or an inventive fusion protein is added to a sample containing leptin binding protein and leptin. The incubation is generally carried out for a limited period of time, in this case for example 6, 12, 18 or 24 hours. The term incubation has to be understood primarily as prior step - for example for a period of 6, 12, 18 or 24 hours - before the start of the quantitative measurement (for instance with a commercially available test kit ) using antibody B for ligand (leptin) detection.

In another preferred embodiment of the method according to the present invention, the leptin-binding protein is a physiological partner of the ligand.

The method according to the present invention is also useful, when the ligand and/or the leptin-binding protein has been added externally (exogenously), e.g. following an injection or other uptake of, for instance, leptin as a ligand in patients or test persons.

10

The present inventive method can be used to measure any ligand of "binding proteins". Binding proteins are proteins interacting with other proteins. An example of a binding protein is leptin-binding protein or the leptin-receptor, interacting with leptin. The binding protein, as used in a method according to the present invention, is preferably soluble, more preferably a soluble (leptin-)receptor.

15

In a preferred embodiment of the method according to the present invention, the ligand as bound by a "binding protein" is a peptidic compound and/or a hormone, preferably a peptidic hormone, in particular leptin, or a hormone-binding protein.

20

The term "peptidic" is to be understood here to comprise any compound, of which constituents are predominantly linked together by a peptidic bond (such as  $R_1-NH-C(O)-R_2$ ).

25

Hormone binding proteins, if used as ligands in the inventive method, are preferably binding proteins (see below), that bind affine hormones. A "hormone" herein is to be understood as a chemical messenger substance, that acts at a distance from its site of synthesis and liberation. Hormones are preferably produced by endocrinal glands, for instance the hypophysis, gonads or epiphysis. Examples are the growth hormone or the luteinizing hormone LTH, insulin, melatonin, glucagon, gastrin, an-

giotensin, substance P, interleukines, vasopressin, endorphines, enkephalines, relaxin, the atrionatriuretic factor or also leptin.

In a specifically preferred embodiment of the method according to the present invention, the ligand used in such a method is human leptin and the leptin-binding protein is human leptin-binding protein. Furthermore, the antibody A or an inventive fusion protein is preferably directed to the binding site of leptin on the leptin-binding protein.

- Moreover, it is preferred to add a further antibody B, preferably a monoclonal antibody B, if a ligand of the binding protein according to the inventive method is quantitatively determined. Such an "antibody B", preferably a "monoclonal antibody B", is typically an anti-ligand-antibody, i.e. an antibody, which is directed to any ligand according to the present invention but not to leptin-R or leptin-BP. It is advantageous, if quantitative determination in the inventive method is carried out by using a competitive binding test, preferably a "radio-immuno assay" (RIA). Likewise it is typically favourable to quantitatively determine the ligand concentration by reading out a signal, which depends on the concentration of the ligand to be determined, preferably by using an enzyme-linked immuno sorbent assay (ELISA) and/or an according sandwich-assay.

- In another preferred embodiment of the method according to the present invention, no separation of the leptin-binding proteins from the sample to be determined is effected prior to quantitative determination. In particular, this means, that it is not required for the invention disclosed to extract the leptin-binding protein from the sample prior to its quantitative analysis, in contrast to the state-of-the-art methods for the determination of ligand concentrations. In the art, practically each form of extraction is carried out, in which the ligand to be determined – such as for instance the hormone – remains in the sample, while the binding protein is separated from the sample, e.g. by precipitation and/or filtration with determined molecule weight

exclusion limits, chromatographic methods, such as e.g. affinity chromatography or HPLC, dialysis in determined ligand sizes etc. Precisely this step can be avoided, preferably while using the method according to the present invention. Due to the selection of antibody A or an inventive fusion protein, neither antibody A/the inventive fusion protein nor the complex formed of antibody A/the inventive fusion protein and leptin-binding protein is able to bind to the ligand to be determined. Therefore, in the sample determination is no longer interfered or falsified by ligand/binding protein interaction, even if the complexed leptin-binding protein remains in the sample. However, use of the highly affine antibodies B for quantitative measurement does not interfere, since they do not bind to antibody A/the inventive fusion protein, to the leptin-binding protein or the complex formed by both, but exclusively to the ligand itself.

This advantage is in particular observed in an especially favourable and preferential method according to the present invention, in which the antibody A/the inventive fusion protein is added in such a way, that subsequent to addition the molar concentration of antibody A is equal or preferably higher than the molar concentration of the leptin-binding protein, preferably at least 50 % higher, more preferably at least twice as high, more preferably at least three times as high and in particular at least four times as high as the leptin-binding protein concentration.

Precisely, this addition of the antibody A/the inventive fusion protein in excessive amounts to the leptin-binding protein is especially favourable, since in the presence of a sufficient excess of antibody A/the inventive fusion protein all ligands are displaced entirely from the leptin-binding protein and therefore become measurable. Since the leptin-binding protein is quantitatively complexed, it does not interfere any more with ligand concentration.

The correct and sufficient amount of specific antibody A or of inventive fusion protein to be added to the sample in order to provide a quantitative measurement of the



ligand without interference phenomena, can be determined by the expert by simple preliminary tests. The optimal addition depends on the amount of a leptin-binding protein in the sample and eventually on the quantitative test system used or the amount of ligand to be determined.

5

In a preferred embodiment of the present invention a ligand is quantitatively determined by using antibody B, directed to the ligand, preferably a monoclonal antibody B, in a sample containing human blood. Therein, the ligand and a leptin-binding protein are preferably contained in solubilized or suspended form, and antibody A/an inventive fusion protein is directed to the binding site of the ligand on the leptin-binding protein. Preferably the deposited monoclonal antibody ZMC2, is added as antibody A to the sample to be determined in significant excessive amounts as compared to the amount of leptin-binding protein, before or during quantitative determination of the ligand, preferably before step b (quantitative determination, by adding and incubating antibody B).

10  
15

Preferably, the ligand as used in a method according to the present invention is leptin.

The present inventive method typically prevents interference of the leptin-binding protein with leptin by adding highly excessive amounts of a specific, preferably monoclonal antibody A, or an inventive fusion protein to the sample to be determined. Antibody A or an inventive fusion protein are directed to the leptin-binding protein. An antibody A as used in the inventive method is preferably the monoclonal antibody ZMC2. It has been selected due to its particularly preferred property to bind to the leptin-binding protein-molecule exactly at the same binding site as the leptin molecule does. If excessive amounts of antibody A are added, it leads to a displacement of the leptin molecules from their binding to the leptin-binding protein. Leptin is "released" and may then be measured by any immunoassay for leptin without sterically induced blocking by leptin-binding protein. Since the "anti-leptin-

20  
25  
30

binding protein-antibody" (antibody A) itself or the inventive fusion protein itself do not interfere with the "anti-leptin antibodies" (antibody B) used for the measurement of leptin (ligand), removal of the complexes consisting of antibody A/inventive fusion protein and leptin-binding protein from the sample is irrelevant. Practically, e.g. special anti-leptin-binding protein antibody ZMC2 with its leptin-displacing property or an inventive fusion protein is added to the sample before the analysis. After incubation with ZMC2 ligand determination follows the respective manufacturer's guidelines.

- 10 Another embodiment of the invention relates to a medicament or a vaccine containing at least one inventive antibody A and/or at least one inventive fusion protein. Preferably, a medicament or a vaccine is disclosed, which contains at least one antibody A or an inventive fusion protein according to the present invention and optionally additives and/or adjuvants. Eventually, further active substances may be present in the medicament or vaccine according to present invention.

The medicament or vaccine containing at least one antibody A and/or an inventive fusion protein according to the present invention is suitable, for instance for the treatment of excessive leptin levels. The inventive antibody may inhibit - preferably entirely - all leptin receptor binding sites. As a consequence, leptin cannot bind to its leptin receptor and/or the therapeutic antibody A/the inventive fusion protein displaces leptin, which is bound to a leptin-binding protein, from its binding site.

According to a further embodiment, an antibody A/the inventive fusion protein according to the present invention or a medicament or vaccine containing at least one inventive antibody A/the inventive fusion protein may be used therapeutically as a leptin-antagonist or may be used for the preparation of a medicament, that inhibits the physiological effect of human leptin. The physiologic effect is blocked by an antibody A/the inventive fusion protein according to the present invention due to its binding to the leptin binding site of the leptin-binding receptor.

A medicament or vaccine, containing one or more antibodies A according to the present invention (and, if applicable, further adjuvants or additives) and/or an inventive fusion protein, can therefore be used for therapeutic purposes also in any of those diseases, disorders or conditions showing unphysiologically increased leptin levels. This also implies, according to the present invention, the use of such inventive antibodies A/fusion proteins, medicaments or vaccines containing at least one antibody A for the treatment (or for the preparation of a medicament for the treatment) of all those disorders, diseases or pathophysiologies, for which excessive leptin levels are etiological, for example diseases of the energy metabolism, pathologic eating disorders, such as anorexia or cachexia. The inventive antibodies A or an inventive fusion protein, medicaments or vaccines, containing an antibody A, may also be used in the treatment of TH1 mediated diseases including multiple sclerosis, diabetes, type 1 diabetes, chronic heart failure (CHF), TNF-mediated diseases, autoimmune colitis, rheumatoid arthritis, systemic lupus erythematosus, and transplant rejection, for the regulation of increased proliferation of naturally occurring regulatory/suppressor T cells and treatment of diseases associated therewith, and diseases associated with the MAPK/ERK1-2, AKT, p-27-kip1 signalling pathways.

Moreover, there are experimental results that document a correlation of leptin values and autoimmune disorder disposition.

The inventive antibodies A, medicaments or vaccines, containing an antibody A or an inventive fusion protein, may also be used to block immune effects of leptin. The inventive antibodies A, fusion proteins, medicaments or vaccines, containing an antibody A or a fusion protein, therefore may be used for immune therapy.

By administration of at least one antibody A according to the present invention, or an inventive fusion protein or the respective inventive medicaments or vaccines, the effects of pathophysiologically increased extra-cellular leptin-concentration can be

blocked without decreasing its serum concentration. Therefore, it is highly useful and promising, to use the inventive medicament or vaccine also for the treatment of diseases such as anorexia nervosa and in the different stages of cachexia. The hypersecretion of leptin in the case of insulin-dependent diabetes mellitus, which is made responsible for a variety of sequelae, may also be treated by an leptin-antagonist according to the present invention or a medicament or vaccine containing at least one antibody A.

Where appropriate, a therapeutic treatment of affected patients with excessive leptin levels may be carried out in combination with such medicaments or active substances, that decrease the secretion of leptin.

A medicament or a vaccine according to the present invention, an inventive antibody A or an inventive fusion protein is particularly preferred or may serve for the preparation of a medicament, for the treatment of conditions, that are associated with an undesired activation of the immune system as well as with autoimmune diseases. Autoimmune diseases may be selected e.g. from multiple sclerosis (MS), rheumatoid arthritis, diabetes, diabetes type I, systemic lupus erythematosus (SLE), chronic polyarthritis, Basedow's disease, autoimmune forms of chronic hepatitis, colitis ulcerosa, allergic type I-diseases, allergic type II-diseases, allergic type III-diseases, allergic type IV-diseases, fibromyalgia, alopecia, Morbus Bechterew, Morbus Crohn, Myasthenia gravis, neurodermitis, polymyalgia rheumatica, progressive systemic sclerosis (PSS), psoriasis, Reiter-syndrome, rheumatic arthritis, vasculitis, etc..

In a specific embodiment, a medicament according to the present invention, an inventive antibody A or an inventive fusion protein may be used or may serve for blocking peripheral effects of leptin. "Peripheral" effects are evoked by inhibiting leptin effects indirectly via blocking the leptin receptor. In contrast, "central" inhibition of leptin are due to direct interaction of a therapeutic compound with leptin.

Leptin acts peripherically e.g. on the immune system, whereas central effects are based on its binding to central control organs, e.g. the hypothalamus. Leptin's binding to the hypothalamus leads to weight control effects. For the treatment of certain immune disorders the interaction of leptin with its receptor shall be inhibited, 5 whereas the leptin level in the other body parts (e.g. hypothalamus) shall remain unchanged in order to avoid considered weight loss/weight gain.

State-of-the-art treatment of leptin excess e.g. by administering anti-leptin-antibodies, lowers the leptin level in the body. Upon administration of anti-leptin-antibodies positive effects on the patient's immune disorder may be achieved. 10 However, simultaneous side effects may appear, such as weight gain due to decreased levels of free leptin, e.g. at the hypothalamus. The inventive antagonist allows to avoid the side effects induced by state-of-the art anti-leptin-antibodies. The anti-leptin-receptor antibody therapy according to the present invention as disclosed 15 herein does not reduce the patient's leptin level by selectively blocking the leptin receptors of certain tissues without modifying the leptin responsiveness of other tissues ("central" effect in the hypothalamus). By way of example, while using an inventive antibody A, such as ZMC2, one might prevent an immune response without having an effect on weight, i.e. there is no significant change in weight during 20 treatment with the inventive antibody A, e.g. ZMC2, or the inventive fusion protein.

Typically, an inventive antibody A or an inventive fusion protein as used in a medicament or a vaccine according to the present invention will be available as lyophilized powder, containing between 0.5 mg and 100 mg of the inventive anti- 25 body A, and further additives, as for example glycine, mannitol, and/or sodium phosphate monohydrate. This lyophilized powder is provided in a suitable aqueous solution and administered subsequently, for example subcutaneously once or several times per day.

In principle, the medicaments according to the present invention may also be administered as liquid dosage form, in particular in form of injection solutions. Suitable additives and/or adjuvants are e.g. solutions or diluents, stabilizers, suspension mediators, buffer substances, preservatives, as well as colorants, expanders, and/or binders. The selection of the adjuvants as well as of the amounts to be administered depends on whether the medicament shall be administered parenterally, intravascularly, intravenously, intraperitoneal or intramuscular. Preparations in form of suspensions and solutions as well as dry preparations, which allow an easy reconstitution, are suitable for all the parenteral applications.

Another embodiment of the invention is a diagnostic agent containing at least one antibody or fusion protein according to the present invention as well as, where appropriate, additives and/or adjuvants. A "diagnostic agent" is to be understood as a preparation or an adjuvant which may be useful, for example for the diagnosis of a determined disease.

A further embodiment of the invention is a kit containing distinct from each other at least one first preparation containing at least one antibody A or fusion protein according to the present invention and one operating test assay ready for use, based on an antigen/antibody-reaction, for the quantitative determination of a ligand, that serves as an antigen in this test.

A kit is to be understood as a conjunct form of different constituents in a packaging form. In this case it is in particular a diagnostic-kit, that contains the different constituents required for the quantitative analysis of a ligand.

A kit is preferred, in which the first preparation contains an antibody A or fusion protein, directed to the binding site of the ligand, preferably leptin, especially preferentially human leptin, on the, preferably human, leptin-binding protein, and/or which contains, apart from the first preparation and the operative test assay ready

for use, based on an antigen/antibody-reaction, for the quantitative determination of a ligand, also a preparation for the calibration.

An especially preferable embodiment is a kit according to the present invention, in which the first preparation contains the antibody ZMC2 (deposited, see above) and/or the preparation for the calibration and/or the antibody B in the enclosed operating test assay ready for use, wherein the test assay is based on an antigen/antibody-reaction for quantitative determination of a ligand, wherein antibody B, preferably a monoclonal antibody B, is directed to the ligand.

Preferably, the ligand is leptin and the antibody B is directed to the main isoform of leptin with a molecular weight of 16 kDa.

A further embodiment of the invention is the use of at least one antibody for determination, preferably quantitative determination, of a physiological ligand, preferably leptin, of a physiological leptin-binding protein.

A further subject matter of the invention is a method for preparing an antibody according to the present invention, i.e. an antibody directed to a leptin-binding protein, which is further directed to a ligand, comprising the following steps: (a) immunization of animals with recombinantly produced leptin-binding protein, (b) isolation of immune cells from the animal, (c) fusion with myeloma-cell lines to hybridoma cell cultures, (d) selection of clones with high specificity for the leptin-binding protein. The immunization can be carried out with all animals suitable for such purposes, such as mice, rabbits, pigs, horses etc. In order to separate such clones, that produce antibodies directed to a leptin-binding protein, from inventive clones (that produce antibodies, which are e.g. specifically directed to the ligand binding site of the leptin-binding protein), suitable media (e.g. wells of microtiter plates, polystyrol beads, plastic tubes) are each coated with one (unselected) anti-leptin-capture anti-

body in a method step (e). In another method method (f), the leptin-binding protein and subsequently the ligand (e.g. leptin) are added. Thereby, the ligand should be preferably labeled (for example by using biotinylation, label (radioactive label, fluorescence marker, enzyme marker (horseradish-peroxidase) etc.)) or be detectable by using a respective anti-ligand-antibody, such that the property of the ligand, to bind to the leptin-binding protein in the recipient coated with capture antibody can be examined. Thus, alternative methods are for instance radioactivity, chemoluminescence, colorimetric methods or an enzyme reaction. After the washing step, those "wells" or "beads" that do not show a signal after the addition of the ligand, can be identified. In this case, the capture antibody blocks the ligand binding site. Thus, the binding site is not available any more for the binding of the ligand, since the capture antibody interferes with the ligand.

Finally, an antibody A or a fusion protein according to the present invention can be identified with by carrying out competitive binding assays. As described above, a coating process is required here, though, in this method each well (e.g. of a microtiter plate) is coated with an anti-leptin-binding protein-antibody, that does not specifically recognize the ligand binding site. After addition of the leptin-binding protein, a potentially interesting antibody or a fusion protein (each with the property of specifically recognizing the ligand binding site) is added to each well above with labeled ligand. As the concentration of the antibody specific for the ligand binding site increases, the signal intensity of the ligand in the well decreases. This method may be used for selection of inventive antibodies directed to a leptin receptor and/or a leptin-binding protein.

25

As an alternative to using hybridoma cells, so-called "phage display" methods (Morphosys or Cambridge Antibody Technologies) may be used, in order to generate potentially inventive antibodies and to select them, as described above.



In the following section, the invention is described in a more detailed way by examples, without limiting the scope of the present invention to these Examples.

## 5 Examples and Figures:

### Description of Figures:

10 Figure 1: shows the results of the examination in Example 2. The results prove, that addition of the inventive antibody may diminish or abolish the influence, which leptin mediates via the leptin receptor.

Figure 2A: shows the protein sequence of the ZMC2/F<sub>ab</sub> light chain (amended).

15 Figure 2B: depicts the nucleotide sequence of the open reading frame of the pComb3/ZMC2,F<sub>ab</sub> vector (light chain) and its translation into the encoding protein sequence of ZMC2/F<sub>ab</sub> light chain (cf. also Figure 2A). Start and stop codons are indicated in bold letters, restriction sites are underlined, and primers sequences are double underlined. The sequence of the pComb3/ZMC2,F<sub>ab</sub> vector is indicated in italic letters.

20

Figure 3A: depicts the protein sequence of ZMC2/F<sub>ab</sub> Heavy chain-His.

25 Figure 3B: shows the nucleotide sequence of the open reading frame of the pComb3/ZMC2,F<sub>ab</sub>-His vector (heavy chain) and its translation into the encoding protein sequence of the heavy chain of ZMC2/F<sub>ab</sub> Heavy chain-His (cf. Figure 3A). Start and stop codons are indicated in bold letters, Restriction sites are underlined, and primers sequences are double underlined. The sequence of pComb3/ZMC2,F<sub>ab</sub>-His vector is

indicated in italic letters. The His-tag is indicated by a dotted (.....) line.

Figure 4A: discloses the nucleotide sequence of the high affinity clone ZMC2 ScFv (1C3). The  $V_L$  sequence is indicated in bold letters. The  $V_H$  sequence is double underlined. The linker in between is indicated in normal letters. The sequence of the vector is indicated in italic letters. The E-tag is indicated by a dotted line. Restriction sites (SfiI and NotI) are underlined, and primers sequences are double underlined.

Figure 4B: shows the translated protein sequence encoded by the nucleotide sequence of the high affinity clone ZMC2 ScFv (1C3) as shown in Figure 4A. Disclosed is the sequence from  $V_H$  until the end of the E-tag.

Figure 5A: depicts the nucleotide sequence of the ZMC2 Heavy chain – Leptin construct. Disclosed is the 1203 bp nucleotide sequence, wherein start and stop codons are indicated in bold letters and restriction sites are underlined. The ZMC2 heavy chain is indicated by a dotted (.....) line, the  $(G_4S)_4$  linker is double underlined. The sequence of Leptin indicated by a (\_\_\_\_) line and the vector is indicated in italic letters. The his tag is indicated by a (.....) line.

Figure 5B: shows the translated protein sequence of the ZMC2 Heavy chain – Leptin construct (cf. Figure 5A). The ZMC2 heavy chain is indicated by a dotted (.....) line, the  $(G_4S)_4$  linker is double underlined. The sequence of Leptin indicated by a single line and the vector is indicated in italic letters. The his tag is indicated by a (\_\_\_\_) line.

Figure 6: illustrates the binding of ZMC2 antibody to human leptin-R on ELISA. Figure 6 clearly shows that ZMC2 antibody binds to human leptin-R in a dose dependent manner (cf. Example 3).

5 Figure 7: shows a bar plot indicating the results of a competitive binding experiment of a ZMC2 antibody to human leptin-R in the presence of (excess) Leptin. On the x-axis different concentrations of leptin (ng/ml) are indicated (10000, 1000, 100, 10, 1, and 0,1 ng/ml) and ZMC2 in a concentration of 10 ng/ml). The y-axis shows the absorbance at 450 nm (OD 450 nm). As can be seen, the binding of ZMC2 to leptin-R is  
10 apparently very strong. Only a large excess of leptin can displace the binding of ZMC2 antibody to human leptin-R (cf. Example 4).

Figure 8: shows a bar plot of the dose response of luciferase activity in response to leptin stimulation in HEK293 cells. Therefore, HEK293 cells were transiently transfected with Ob-Rb and a STAT3-luciferase reporter construct and stimulated with varying doses of leptin for 2 hours. Then, luciferase activity was measured and was corrected for B-galactosidase. On the x-axis different concentrations of leptin (ng/ml) are indicated (1, 5, 10, 20, 50, 100, 250, 1000 ng/ml). The y-axis shows the degree of fold induction versus unstimulated cells. As can  
15 be obtained from Figure 8, induction of HEK293 cells with leptin reaches a maximum level, whereby nearly no further stimulation is observed (cf. Example 5).

25 Figure 9: illustrates in a bar plot the dose response for inhibitory effects of ZMC2 antibody on leptin signalling. HEK293 cells were transiently transfected with leptin-R and a STAT3-luciferase reporter construct and stimulated with leptin (5ng/ml) for 2 hours. Different doses of ZMC2 antibody (ug/ml, see x-axis) were added to the culture,  
30

luciferase activity was measured and corrected for B-galactosidase. The results are expressed as fold induction over the unstimulated cells. On the x-axis different concentrations of leptin (ng/ml) (0, 12,5 and 100 ng/ml) and ZMC2 (10, 5, 1, 0,5, and 0,1 ng/ml) are indicated. As can be obtained from Figure 9, ZMC2 antibody demonstrated inhibitory effects on leptin signalling in a dose response manner (cf. Example 6).

Figure 10: shows a bar plot of the binding of ZMC2 antibody to mouse leptin-R. Binding of ZMC2 antibody was detected using a biotinylated secondary antibody followed by SAV-HRP. The OD of the resulted colour was measured at 450nm. On the x-axis different concentrations of leptin (ng/ml) and ZMC2 (ng/ml) are indicated. As may be seen in Figure 10, ZMC2 antibody binds to mouse leptin-R in a dose dependent manner and its binding can be displaced by leptin at high concentrations of leptin only (cf. Example 7).

Figure 11: illustrates in a bar plot the blocking of TNF- $\alpha$  production in leptin activated human monocytes by ZMC2 antibody. Human monocytes were cultured in the presence of PBS, Leptin (250 ng/ml), ZMC2 (10 ng/ml) + Leptin and ZMC2 (5 ng/ml) + Leptin. The Y axis shows percentage of monocytes expressing TNF- $\alpha$  (cf. Example 8).

Figure 12A depicts a proliferation assay showing the stimulation by okt3 (optimal dose 100ng/ml) of human PBL in autologous human serum in the presence of ZMC2 ab in different concentrations. In Figure 12A ZMC2 is shown (from 0,01, 0,1, 1 and 10 ug/ml) in the presence or absence of exogenous leptin (100ng/ml). As may be obtained from Figure 12A, there is a minor effect of ZMC2 to increase PBL proliferation that is reduced by leptin (cf. Example 9).

Figure 12 B shows the stimulation by okt3 (optimal dose 100ng/ml) of human PBL in autologous human serum with different doses of leptin and more points on ZMC2 mAb dose response (0, 0.005, 0.05, 0.5, 5, 50 ug/ml) are shown. The curve in Figure 12B, is biphasic with a slight tendency to increased proliferation after treatment with ZMC2 which is again reduced by leptin (cf. Example 9).

Figures 12C-D: show comparative experiments carried out with a donor (in the same assay as shown for Figures 12A and B) with an agonistic anti-leptin receptor ab from R&D systems and another anti-human leptin treatment from R&Dsystems. The agonistic anti-ObR2 antibody increases proliferation in a similar fashion to the antagonistic ZMC2 and the anti-leptin at low doses increases the proliferation. The proliferation then is reversed by leptin when using ZMC2, whereas it is still stimulated with anti-ObR2. On a mixed population of naive/memory cells; with leptin present in serum controlling memory cell proliferation, the addition of the blocking ab ZMC2 thus slightly increases proliferation which can then be reversed. Thus, ZMC2 is acting as an antagonistic antibody (cf. Example 9).

Figure 13: shows a plot of the results from a proliferation assay similar to those as disclosed in Figure 12, but extended to a longer time period (proliferation at 4 days (96 h)). Figure 13 shows the stimulation by okt3 (optimal dose 100ng/ml) of human PBL in autologous human serum with different doses of leptin and more points on ZMC2 mAb dose response (0, 0.005, 0.05, 0.5, 5, 50 ug/ml) are shown. ZMC2 antibody stimulates proliferation, which is then clearly reversed by addition of leptin. Thus, ZMC2 clearly reacts as an antagonist to leptin-R regarding the overall response on the mixed T-cell population (cf. Example 10).

Figures 14A-C: show a plot of food uptake experiments (cf. Example 11) on ob/ob and ob/+ mice: 3 mice groups were selected; all females; The mice were initially treated with low dose leptin such as to keep the weight constant. The treatment was 100ug/daily ip+Rec leptin 0.5ug/gr weight, for 5 days. In Figure 14A, percent in body weight change is flat during treatment with leptin alone, and instead of being prevented by ZMC2, the weight was slightly increased in terms of no change or even little reduction in body weight. On the heterozygotes (Figure 14B, cf. Example 11), treated in parallel, basically show the similar results. With the same dose of ZMC2 alone, the untreated mice slightly increase body weight over the time; In a comparative Experiment (Figure 14C, cf. Example 9) proliferation of spleen cells from normal mouse (B6) was stimulated with anti-CD3 for mouse (called 2C11) (0,0001, 0,001, 0,01, 0,1, 1, 10, 100 ug/ml) dose response in the presence of FCS 2%. As can be seen in Figure 14C, a clear inhibition can be obtained at 10-100 ug/ml.

Figure 15: displays a photograph of a gelelectrophoresis. The samples applied on the gel were obtained from an anti-CD3 stimulation experiment using T-cells from autoimmunity-prone NOD mice. As may be obtained from the gel ERK1/2 phosphorylation is reduced by the leptin-R blocking antibody.

Figure 16: shows a plasmid map of the pComb3/ZMC2 F<sub>ab</sub>-His clone.

Figure 17: shows the results of a Western Blot experiment during purification of recombinant F<sub>ab</sub> ZMC2. As can be obtained from the Western Blot, recombinant F<sub>ab</sub> ZMC2 is expressed in the soluble fraction and the Blot shows a protein of the correct size of Kappa light chain.

Figure 18: shows the results of a Western Blot experiment during purification of recombinant His-tagged F<sub>ab</sub> ZMC2. As can be obtained from the Western Blot, His tagged F<sub>ab</sub> ZMC2 can be purified on a Cobalt Column.

5

Figure 19: shows a Coomassie Blue staining of a polyacrylamide gel of a purified F<sub>ab</sub> ZMC2 antibody.

10

Figure 20A: shows a bar plot of a binding experiment of ZMC2 and recombinant expressed F<sub>ab</sub> ZMC2 to human Leptin. The y-axis shows the absorbance at 450 nm (OD 450 nm).

15

Figure 20B: shows the effect of recombinant F<sub>ab</sub> ZMC2 on leptin-induced SIE activation. As can be obtained from Figure 20A recombinant F<sub>ab</sub> ZMC2 (rF<sub>ab</sub>) and chemically made F<sub>ab</sub> ZMC2 (cF<sub>ab</sub>) for ZMC2 block leptin signalling.

20

## Examples

### Example 1:

#### Production of antibody A (directed to leptin-BP )

5

More than 20 Balb/c mice were repeatedly immunized with leptin-BP produced recombinantly according to the generally known method (ref. to leaflet of Titer-max®). When a high titer against leptin-BP was achieved, the spleen has been removed from the animals, and according to the method described by Köhler and Mil-

10 stein (Continuous cultures of fused cells secreting antibody of predefined specificity, Nature, 1975, Aug. 7; 256 (5517): 495-7) hybridoma cell cultures were produced by fusion with a mouse-myelom-cell line. Also according to generally known methods (limited dilution, screening of the hybridoma cell culture supernatants with labeled antigen) those clones were selected, which produced monoclonal antibody with

15 high affinity and specificity for leptin- BP.

20

The majority of the selected clones were directed to such epitopes on the leptin-BP molecule, that are situated externally of the binding site for leptin. In order to select antibodies A according to the present invention, directed to an epitope within the

20 binding site, at first one of many antibodies, that binds leptin-BP externally of the binding site, was used. It was identified by applying all monoclonal antibodies against leptin-BP (as many as possible), e.g. in separate wells each, on a microtiter plate (polystyrol plates with highly adsorptive surface) as capture antibody, (alternatively, other methods, as e.g. coated polystyrol beads, coated plastic tubes etc., may

25 also be used). Subsequently, recombinant leptin-BP has been added, which binds to the coating antibody – in a primarily still unknown arrangement (binding according to each epitope within or externally of the interaction site of the hormone receptor). Finally, labeled (in our case biotinylized) leptin has been added, which may now bind exclusively to the leptin-BP-molecules, and which possess a freely accessible

30 binding site (i.e., where the coating antibody does not interfere with the leptin bind-



ing). Determination of bound antibody was carried out by addition of streptavidin-europium, which binds to an bound biotinylized leptin and can be measured in a fluorimeter (time resolved fluorescence after addition of enhancement solution). Alternatively, this step may also be effected using analog methods (radioactivity, enzyme reaction/colorimetric method or chemoluminescence).

In order to find an antibody, that is directed to the binding site, a microtiter plate was coated with an antibody against leptin-BP, selected according to the above method, that does not interfere with the binding of leptin. The addition of leptin-BP provoked an aligned binding of the leptin-BP-molecules, that is to say with a freely accessible binding site for leptin. Subsequently, biotinylized leptin was added and simultaneously, all other monoclonal antibodies against leptin-BP (once again each antibody in an own well of the microtiter plate). If an antibody is then directed to the binding site, it should block the binding of biotinylized leptin in a concentration dependent manner. This could be detected by a decrease of the signal intensity (detection method in our case again time resolved fluorescence (streptavidin-europium)). For confirmation in an inverted experiment a displacement of biotinylized antibodies directed to leptin-BP by adding unlabeled leptin was carried out. This is possible, if the biotinylized antibody competes with the non-labeled leptin for the binding on the receptor binding site, i.e. if the epitope of the mAbs is located at the interaction site of the leptin/ leptin receptor.

#### Example 2:

Verification of the effectiveness of an antibody according to the present invention and the associated improvement of general quantitative measurement methods in the presence of interfering leptin-binding protein

Leptin-binding protein was immobilized on a microtiter plate such, that the binding site for leptin was freely accessible. This is carried out by using other antibodies directed to the leptin-binding protein, that do not bind within, but externally at the hormone-receptor-interaction site. Subsequently, labeled (biotinylized) leptin was

added. Then, buffer solutions with ascending concentrations of the inventive antibody ZMC2 are added to the incubation solutions. Following an incubation time of 2 hours, the amount of labeled leptin bound to immobilized leptin-binding protein was measured by addition of a fluorescence dye, that binds specifically to biotin.

- 5 With an ascending concentration of ZMC2, the binding of biotinylized leptin decreased, thus proving the displacement effect of ZMC2.

Furthermore, the functional blockade of the leptin receptors was proven in a cell culture assay by using ZMC2. Therefor, HEK293-cells were transfected transiently  
10 with the human leptin receptor as well as with a STAT 3-luciferase-reporter. This construct enables the visualization or the measurement of the intracellular signal cascade activation caused by leptin.

As shown in Figure 1, the addition of leptin to the cell culture provokes a 7-8-fold  
15 increase of the luciferase activity (compared with the control containing no leptin). Adding the inventive antibody ZMC2 to the preparation (5 µg/ml) prevents this activation in contrast to the control antibody (antibody with irrelevant specificity, in this case against KLH).

### 20 Example 3:

#### Binding of ZMC2 antibody to human leptin-R on ELISA

For detecting binding of ZMC2 antibody to human leptin-R an ELISA plate was coated with recombinant human leptin-R (200ng/well) and different concentrations  
25 of ZMC2 antibody (1000, 333, 111, 37, 12,3, 4,1, 1,3, 0,45, 0,15, 0,05, 0,016, 0,005, 0,0018, 0,0006 ng/ml) were added. Binding of ZMC2 antibody to leptin-R was detected subsequently using a biotinylated secondary antibody followed by SAV-HRP and the signal (OD of resulted colour) was measured at 450nm. As a result, ZMC2 antibody binds to human leptin-R in a dose dependent manner as may  
30 be obtained from the corresponding bar plot (see Figure 6).

## Example 4:

## Specificity of binding of ZMC2 antibody to human leptin-R

- 5 For a competitive binding experiment of a ZMC2 antibody to human leptin-R in the presence of (excess) leptin, an ELISA plate was coated with recombinant human leptin-R (200ng/well). Different concentrations of leptin (10000, 1000, 100, 10, 1, 0,1 ng/ml) were added to wells in presence or absence of ZMC2 antibody. ZMC2, if added, was present in a concentration of 10 ng/ml. Binding of ZMC2 antibody was
- 10 then subsequently detected using a biotinylated secondary antibody followed by SAV-HRP and the signal (OD of resulted colour) was measured at 450nm. As can be obtained from Figure 7 only a large excess of leptin can displace the binding of ZMC2 antibody to human leptin-R. Accordingly, binding of ZMC2 antibody to leptin-R is highly specific.

15

## Example 5:

## Dose response of luciferase activity in response to leptin stimulation

- In order to detect a dose response of luciferase activity in response to leptin stimulation, HEK293 cells were transiently transfected with leptin-Rb and a STAT3-luciferase reporter construct and stimulated with varying doses of leptin for 2 hours.
- 20 After 2 hours the media were replaced with fresh medium containing no leptin and cultures were inoculated for further 4 hours before the cells were lysed. Subsequently, luciferase activity was measured and corrected for  $\beta$ -galactosidase, which
- 25 was used as a transfection control. The results are shown in Figure 8. The values shown express the fold induction over the unstimulated cells. The induction is dose dependent and reaches a maximum at about 50 – 1000 ng/ml Leptin.

30

## Example 6:

## Dose response for the inhibitory effects of ZMC2 antibody on leptin signalling

To obtain a dose response for the inhibitory effects of ZMC2 antibody on leptin signalling HEK293 cells were transiently transfected with leptin-Rb and a STAT3-luciferase reporter construct and stimulated with leptin (5ng/ml) for 2 hours. Different doses of ZMC2 antibody (10, 5, 1, 0,5 and 0,1 µg/ml, if leptin is contained) were added to the culture 30 minutes prior to addition of leptin (0 ng/ml, if no ZMC2 is contained and 12,5 ng/ml, if ZMC2 is contained). Luciferase activity was measured subsequently and was corrected for β-galactosidase. The results are shown as a bar plot in Figure 9, being expressed as fold induction over the unstimulated cells. As a result ZMC2 antibody demonstrated inhibitory effects on leptin signalling in a dose response manner.

## Example 7:

## Binding of ZMC2 antibody to mouse leptin-R

An ELISA plate was coated with recombinant mouse leptin-R (200ng/well) and different concentrations of ZMC2 antibody, leptin, growth hormone or the combination of them (ng/ml) were added. Binding of ZMC2 antibody was detected using a biotinylated secondary antibody followed by SAV-HRP and the OD of resulted colour was measured at 450nm. The results are shown in Figure 10 as a bar plot. As can be obtained from the plot ZMC2 antibody binds to mouse leptin-R in a dose dependent manner and its binding can be displaced by leptin only at high doses.

## Example 8:

## Blocking of TNF-α production in leptin activated human monocytes by ZMC2

For this experiment, TNF-α production was induced by leptin activated human monocytes. After inducing TNF-α production, ZMC2 (10 and 5 ng/ml) was added to

the monocytes in the presence and absence of leptin (250 ng/ml). The results are shown in Figure 11. As can be seen in Figure 11, ZMC2 is capable of blocking TNF- $\alpha$  production by leptin activated human monocytes. Y axis shows percentage of monocytes expressing TNF- $\alpha$  (% double positive (CD-14 and TNF- $\alpha$  positive) monocytes).

#### Example 9:

Stimulation of human PBL in autologous human serum by okt3 (anti-CD3 experiment)

For measuring the stimulation of human PBL in autologous human serum by okt3 (optimal dose 100ng/ml) cells were inoculated in the presence of ZMC2 ab (from 0, 0.1, 1 and 10 ug/ml) and in the presence or absence of exogenous leptin (100ng/ml). Cells were harvested after 60 min allowing maximum DNA synthesis.

The proliferation was measured (cpm) and can be seen in Figure 12A. There is a minor effect of ZMC2 to increase PBL proliferation that is reduced by leptin. This increase in proliferation can be reversed by leptin, as can be seen in the following experiments. ZMC2 thus acts as an antagonist. Furthermore, it is considered that the response to anti-CD3 stimulation in humans in the presence of leptin is dependent on the relative proportion of naive/memory cells in PBL; the more naive cells are present the greater is the increase in proliferation in response to leptin; alternatively, the more memory cells are present the greater is the inhibition of proliferation induced by leptin (although IFN-g secretion is increased, despite the reduced proliferation of memory cells).

In Figures 12B, C and D stimulation by okt3 (optimal dose 100ng/ml) of human PBL in autologous human serum with different doses of leptin (10 and 100 ng/ml) and more points on ZMC2 mAb dose response (0,0001, 0,001, 0,01, 0,1, 1, 10, 100 ug/ml) is shown. As can be seen, the curve is biphasic with a slight tendency to increased proliferation after treatment with ZMC2 (Figure 12B) which is again reduced

by leptin; with donor 2 experiments were performed in the same assay, i.e. the agonistic anti-leptin receptor ab (anti-ObR2) from R&D systems (Figure 12 C) and another anti-human leptin treatment from R&D systems (Figure 12 D). anti-ObR2 increases proliferation in a similar fashion to ZMC2 and the anti-leptin at low doses  
5 increases the proliferation, which is reversed by leptin. Here, the effects on a mixed population of naive/memory cells are studied, wherein leptin is present in serum controlling memory cell proliferation. Addition of the blocking ab ZMC2 slightly increases proliferation, which can be reversed upon addition of leptin. Thus, ZMC2 is acting as an antagonistic antibody, whereas anti-ObR2 acts as an agonistic anti-  
10 body.

#### Example 10:

##### Elongated proliferation experiments

15 To better define the effect of ZMC2, proliferation experiments were carried out over a longer time period to see whether the increase in proliferation was more visible when cells were to be in a later phase of cell cycle. Therefore, proliferation was measured at 4 days (96 h), and surprisingly the ZMC2 ab still stimulated proliferation, wherein - looking at the overall response on a mixed T cell population - ZMC2  
20 turned out to act as an antagonist, since addition of leptin reduces proliferation (see Figure 13). The specificity of ZMC2 additionally can be measured by the fact that addition of leptin reduces proliferation.

#### Example 11:

25 Food uptake experiments on ob/ob and ob/+ mice: 3 mice group

For food uptake experiments ob/ob and ob/+ mice, all females, were taken. In case of ob/ob, mice were treated with low dose leptin in order to maintain weight, i.e. not to loose weight but also not to increase weight, as it usually happens. Usually 1  
30 gram of body weight every 2 days is typically fed to the mice. The treatment in the

experiment was 100ug/daily ip+Rec leptin 0.5ug/gr weight, for 5 days. As can be seen in Figure 14A the curve in %in body weight change is flat during treatment with leptin alone, indicating that the treatment was working. Instead of being prevented by the ab, body weight was slightly increased in terms of no change in body weight. In an comparative Experiment heterozygous mice (see Figure 14B), were used because they show a lower leptin than normal mice. The heterozygotes were treated in parallel with the same dose of ab alone. The untreated mice showed a tendency to increase body weight over the time (less strong than for the the ob/ob mice); the ab treated were similar for body weight, but after stopping body weight increased more than the controls.

#### Proliferation of spleen cells from normal mouse (B6)

Proliferation of spleen cells from normal mouse (B6) was stimulated with anti-CD3 for mouse (called 2C11) (0,0001, 0,001, 0,01, 0,1, 1, 10, 100 ug/ml) dose response in the presence of FCS 2%. As can be seen in Figure 14C, a clear inhibition can be obtained at 10-100 ug/ml.

## Patent claims

1. Antibody A directed to a leptin receptor and/or a leptin-binding protein, characterized in that it substantially reduces and preferably prevents the interaction of the leptin receptor and/or of the leptin-binding protein with a ligand.
2. Antibody A according to claim 1, characterized in that it is directed to the extracellular domain of a leptin receptor, in particular of a leptin-binding protein.
3. Antibody A according to one of claims 1 to 2, characterized in that it binds on a leptin-binding protein at the binding site for the ligand.
4. Antibody A according to one of claims 1 to 3, characterized in that the ligand is leptin.
5. Antibody A according to one of claims 1 to 4, characterized in that the leptin-binding protein is a physiological leptin-binding protein solubilized or suspended in liquid, preferably in body liquid.
6. Antibody A according to one of claims 1 to 5, characterized in that it is a monoclonal antibody.
7. Antibody A according to one of claims 1 or 6, characterized in that the antibody A is the antibody ZMC2.
8. Antibody A according to one of claims 1 to 7, characterized in that the antibody is humanized and directed to a human leptin receptor or human leptin-binding protein.



9. Antibody A according to one of claims 1 to 8, characterized in that the antibody comprises a sequence selected from any of the protein sequences selected from SEQ ID NO: 1, 2, 3, 4, 6 or 8.
- 5 10. Antibody A according to one of claims 1 to 8, characterized in that the antibody comprises a protein sequence encoded by a nucleic acid sequence selected from SEQ ID NOs: 2, 4, 5, or 7.
- 10 11. Antibody A according to one of claims 1 to 10, characterized in that the antibody is capable of blocking the peripheral actions of leptin without influencing the central actions of leptin.
- 15 12. Fragment of an antibody A according to one of claims 1 to 11, characterized in that the fragment is a  $F(ab')_2$  fragment or a single-chain antibody (scFv) or a fragment of an antibody.
13. Antibody A according to one of claims 1 to 11 or a fragment of an antibody A according to claim 12 as a medicament.
- 20 14. Fusion protein, containing as portion I an antibody according to any of claims 1 to 11 or a fragment of an antibody A according to claim 12, and as portion II an antibody, an antibody fragment or a peptide, preferably leptin.
- 25 15. Fusion protein in accordance to claim 14, characterized in that the fusion protein contains a linker between portion I and portion II.
16. Fusion protein in accordance to claim 15, characterized in that the linker comprises a length of about 5 to 40 amino acids, more preferably between 5 and 30 amino acids and mostly preferred between 5 and 20 amino acids.

17. Fusion protein in accordance to claims 15 and 16, characterized in that the linker contains at least 50% glycine residues, preferably at least 60 %, more preferably at least 70% and most preferably at least 80%.

5 18. Fusion protein according to any of claims 14 to 17, characterized in that the fusion protein is bispecific.

19. Fusion protein according to claim 18, characterized in that the bispecific fusion protein is directed on directed to a leptin receptor and/or a leptin-binding protein as a first specificity and to a cell surface protein as a second specificity.  
10

20. Fusion protein in accordance to any of claims 14 to 19, characterized in that the fusion protein comprises an amino acid sequence encoded by the nucleic acid sequence SEQ ID NO: 7.  
15

21. Fusion protein in accordance any of claims 14 to 19, characterized in that the fusion protein comprises the amino acid sequence SEQ ID NO: 8.

22. Method for quantitative determination of a ligand of a binding protein/receptor in a sample containing the ligand and a leptin receptor and/or a leptin-binding protein in solubilized or suspended form, characterized in that at least one antibody A according to one of claims 1 to 11, a fragment of an antibody A according to claim 12, and/or a fusion protein according to one of claims 14 to 21 is/are be added to the sample to be determined.  
20

25

23. Method according to claim 22, characterized in that at least one antibody A is added before or during, preferably before, the quantitative determination and/or is incubated with the sample.

24. Method according to one of claims 22 or 23, characterized in that the sample contains liquid, preferably body liquid, more preferably human body liquid, e.g. blood.

5 25. Method according to one of claims 22 to 24, characterized in that the ligand of a binding protein/receptor is a ligand of leptin-binding protein and/or leptin-receptor.

10 26. Method according to one of claims 22 to 25, characterized in that the leptin-binding protein is soluble, preferably a soluble portion of the leptin receptor and/or a hormone-binding protein, in particular a soluble hormone-binding protein.

15 27. Method according to one of claims 22 to 26, characterized in that the quantitative determination of the ligand is carried out by using the binding of the ligand as an antigen to an antibody B, preferably a monoclonal antibody B.

20 28. Method according to one of claims 22 to 27, characterized in that the quantitative determination is carried out by using a competitive binding test, preferably a "radio-immuno assay" (RIA).

25 29. Method according to one of claims 22 to 28, characterized in that the quantitative determination is carried out by the measurement of an increasing reading parameter to be increased as a function of the concentration of the ligand to be determined, preferably using an enzyme-linked immuno sorbent assay (ELISA) and/or a sandwich-assay.

30 30. Method according to one of claims 22 to 29, characterized in that the leptin-binding protein is not separated from the sample to be determined before quantitative determination.

31. Method according to one of claims 22 to 30, characterized in that at least one antibody A is added such, that at least one antibody A is present in the sample in a higher concentration than the leptin-binding protein, preferably in a concentration of at least 50 % more, more preferably of at least 100 %, even more preferably of at least 200 % more, and most preferably of at least 400 % more.

32. Method according to one of claims 22 to 31, characterized in that the ligand is leptin.

33. Medicament containing at least one antibody A according to one of claims 1 to 11, a fragment of an antibody according to claim 12, or a fusion protein according to one of claims 14 to 21 as well as, where appropriate, further active agents as well as further additives and/or adjuvants.

34. Diagnostic agent containing at least one antibody A according to one of claims 1 to 11, a fragment of an antibody according to claim 12, or a fusion protein according to one of claims 14 to 21 as well as, where appropriate, adjuvants.

35. Kit containing distinct from each other at least one first preparation containing at least one antibody A according to one of claims 1 to 11, a fragment of an antibody according to claim 12, or a fusion protein according to one of claims 14 to 21 and one operating test assay ready for use, based on an antigen/antibody-reaction, for quantitative determination of a ligand.

36. Kit according to claim 35, characterized in that the first preparation contains the antibody ZMC2 and/or a preparation for calibration and/or an antibody B in the operating test assay ready for use, wherein the test assay is based on an antigen/antibody-reaction for the quantitative determination of a ligand, wherein antibody B is directed to the ligand.

37. Kit according to claim 36, characterized in that the ligand is leptin and the antibody B is directed to the main isoform of leptin with a molecular weight of 16 kDa.

5

38. Kit according to one of claims 35 to 37, characterized in that the antibody B is a monoclonal antibody.

10

39. Kit according to of claim 38, characterized in that the monoclonal antibody B is directed to leptin.

15

40. Use of at least one antibody A according to one of claims 1 to 11, of a fragment of an antibody according to claim 12, or of a fusion protein according to one of claims 14 to 21 for determination, preferably quantitative determination, of a ligand in a physiological solution, that also contains a physiological leptin-binding protein.

20

41. Use of at least one antibody A according to one of claims 1 to 11, of a fragment of an antibody according to claim 12, or of a fusion protein according to one of claims 14 to 21 for preparing a medicament for the treatment of diseases, alterations or pathophysiologies, due to excessive leptin levels, alterations of the energy metabolism, in particular eating disorders, such as anorexia nervosa and cachexia as well as alterations of the immune system, in particular the undesired activation of the immune system and autoimmune diseases, selected from multiple sclerosis (MS), rheumatoid arthritis, diabetes, diabetes type I, systemic lupus erythematosus (SLE), chronic polyarthritis, Basedow's disease, autoimmune forms of chronic hepatitis, colitis ulcerosa, allergic type I-diseases, allergic type II-diseases, allergic type III-diseases, allergic type IV-diseases, fibromyalgia, alopecia, Morbus Bechterew, Morbus Crohn, Myasthenia gravis, neurodermitis, polymyalgia rheumatica, progressive systemic sclerosis (PSS), psoriasis, Reiter-

30

syndrome, rheumatic arthritis, vaskulitis, TH1 mediated diseases including multiple sclerosis, diabetes, type 1 diabetes, chronic heart failure (CHF), TNF-mediated diseases, autoimmune colitis, rheumatoid arthritis, systemic lupus erithematosus, and transplant rejection, for the regulation of increased proliferation of naturally occurring regulatory/suppressor T cells and treatment of diseases associated therewith, and diseases associated with the MAPK/ERK1-2, AKT, p-27-kip1 signalling pathways, for blocking immune actions of leptin or for immune therapy.

42. Use of at least one antibody according to one of claims 1 to 11, of a fragment of an antibody according to claim 12, or of a fusion protein according to one of claims 14 to 21 or of a medicament according to claim 33 for the treatment of diseases, alterations or pathophysiologies, that are due to excessive leptin levels, alterations of the energy metabolism, in particular eating disorders, such as anorexia nervosa and cachexia as well as alterations of the immune system, in particular the undesired activation of the immune system and autoimmune diseases, selected from multiple sclerosis (MS), rheumatoid arthritis, diabetes, diabetes type I, systemic lupus erythematosus (SLE), chronic polyarthritis, Basedow's disease, autoimmune forms of chronic hepatitis, colitis ulcerosa, allergic type I-diseases, allergic type II-diseases, allergic type III-diseases, allergic type IV-diseases, fibromyalgia, alopecia, Morbus Bechterew, Morbus Crohn, Myasthenia gravis, neurodermitis, polymyalgia rheumatica, progressive systemic sclerosis (PSS), psoriasis, Reiter-syndrome, rheumatic arthritis, vaskulitis, TH1 mediated diseases including multiple sclerosis, diabetes, type 1 diabetes, chronic heart failure (CHF), TNF-mediated diseases, autoimmune colitis, rheumatoid arthritis, systemic lupus erithematosus, and transplant rejection, for the regulation of increased proliferation of naturally occurring regulatory/suppressor T cells and treatment of diseases associated therewith, and diseases associated with the MAPK/ERK1-2, AKT, p-27-kip1 signalling pathways, for blocking immune actions of leptin or for immune therapy.

1/20

5




Figure 1

20

2/20

A)

5

XHNPIPMPPAAAGLLLLAAQPAMAELVMTQSPKFMSTSIGDRVNITCKAT  
 QNVRTAVTWYQQKPGQSPQALIFLASNRHTGVPARFTGSGSGTDFTLTIN  
 NVKSEDLADYFCLQHWNYPLTFGSGTKLEIKRADAAPTVSIFPPSSEQLT  
 SGGASVVCFLNNFYPKDINVWKIDGSRQNGVLNSWTDQDSKDYSTYSMS  
 STLTLTKEDEYERHNSYTCEATHKTTSTSPIVKSFNRGEC\*\*SRVKRXQXSG  
 PPGTPIRPIGXPIYNSLGGGFQ

B)

10

DNA: NANGTCATAATCCAATACCTATGCCTACGGCAGCCGCTGGATTGTTATTAC  
 +3: X H N P I P M P T A A A G L L L L  
 pComb3 vector SacI V<sub>L</sub>(κ) primer  
 DNA: TCGCTGCCCAACCAGCCATGGCGAGCTCGTGATGACCCAGTCTCCAAAT  
 +3: A A Q P A M A E L V M T Q S P K F

15

DNA: TCATGTCCACATCAATAGGAGACAGGGTCAATATCACCTGCAAGGCCACTC  
 +3: M S T S I G D R V N I T C K A T Q

20

DNA: AGAATGTCTGCTACTGCTGTTACCTGGTATCAACAGAAACCAGGGCAGTCTC  
 +3: N V R T A V T W Y Q Q K P G Q S P

25

DNA: CTCAAGCACTGATTTTCTTGGCATCCAACGGGCACACTGGTGTCCCTGCTC  
 +3: Q A L I F L A S N R H T G V P A R

DNA: GATTACAGGCAGTGGATCTGGGACAGATTTCACTCTCACCATTAAACAATG  
 +3: F T G S G S G T D F T L T I N N V

30

DNA: TGAAATCTGAAGACCTGGCAGATTATTTCTGTCTACAACATTGGAATTATC  
 +3: K S E D L A D Y F C L Q H W N Y P

DNA: CTCTCACGTTGCGCTCGGGACAAAGTTGGAAATAAAACGGGCTGATGCTG  
 +3: L T F G S G T K L E I K R A D A A

35

DNA: CACCAACTGTATCCATCTTCCCACCATCCAGTGAGCAGTTAACATCTGGAG  
 +3: P T V S I F P P S S E Q L T S G G

DNA: GTGCCTCAGTCGTGTGCTTCTTGAACAACCTTACCCCAAAGACATCAATG  
 +3: A S V V C F L N N F Y P K D I N V

40

DNA: TCAAGTGGAAGATTGATGGCAGTGAACGACAAAATGGCGTCTGAACAGTT  
 +3: K W K I D G S E R Q N G V L N S W  
 BclI

45

DNA: GGACTGATCAGGACAGCAAAGACAGCACCTACAGCATGAGCAGCACCCCTCA  
 +3: T D Q D S K D S T Y S M S S T L T

DNA: CGTTGACCAAGGACGAGTATGAACGACATAACAGCTATACCTGTGAGGCCA  
 +3: L T K D E Y E R H N S Y T C E A T

50

C<sub>L</sub>(κ) primer  
 DNA: CTCACAAGACATCAACTTCACCCATTGTCAAGAGCTTCAACAGGGGAGAGT  
 +3: H K T S T S P I V K S F N R G E C  
 Stop XbaI NotI KpnI

DNA: GTTAGTAATCTAGAGTTAAGCGGCCGCAATCGAGGGGGGGCCCGGTACCCC  
 +3: \* \* S R V K R P Q S R G G P V P Q

55

DNA: AATTCGCCCTATAGGGGNGCCGTATTACAATTCACTGGGCGGCGTTTCA  
 +3: F A L \* G X R I T I H W A A V F X

60

DNA: AN  
 +3:

Figure 2



3/20

A)

LAXRGGGRKIXFXRETIVIMKYLXAYGPAAGLLLLAAQPAMAQVKLLESGP  
 GLVAPSELSITCTISGFSLTDDGVSWIRQPPGKGLEWLGVIWGGGSTYF  
 NSLFKSRLSITRDNSKSQVFLEMDSLQTDDETAMYYCAKHDGHETMDYWGO  
 GTSVTVSSSKTTPPSVYPLAPGSAAQTNMVTLGCLVKGYFPEPVTVTNW  
 SGLSSGVHTFFPAVLQSDLYTLSSSVTVPSSTWPSSETVTCNVAHPASSTK  
 VDKKIVPRDCTSHHHHHH\*ASLVVAVALHSFVXIKANRRPAX

B)

DNA: TTGGCCNCCCGCGGTGGCGGCCGCAAAATTNTATTTNCAAGGAGACAGTC  
 -1: L A X R G G G R K I X F X R E T V

DNA: ATAATGAAATACCTTTTNGCCTACGGGCCAGCCGCTGGATTGTTATTACTC  
 -1: I M K Y L X A Y G P A A G L L L L  
 pComb3 vector XhoI V<sub>H</sub>b primer

DNA: GCTGCCCAACCAGCCATGGCCCAGGTGAAACTGCTCGAGTCAGGACCTGGC  
 -1: A A Q P A M A Q V K L L E S G P G

DNA: CTGGTGGCGCCCTCAGAGAGCCTGTCCATCACATGCACTATCTCAGGGTTC  
 -1: L V A P S E S L S I T C T I S G F

DNA: TCATTAACCGACGATGGTGTAAAGCTGGATTCCGCGAGCCTCCAGGAAAGGGT  
 -1: S L T D D G V S W I R Q P P G K G

DNA: CTGGAGTGGCTGGGAGTAATATGGGGTGGTGAAGCACATACTTTAATTCA  
 -1: L E W L G V I W G G G S T Y F N S

DNA: CTTTTCAAATCCAGACTGAGCATCACAGGGACAACCTCTAAGAGCCAAGTT  
 -1: L F K S R L S I T R D N S K S Q V

DNA: TTCTTAGAAATGGACAGTCTACAAACTGATGACACAGCCATGTACTACTGC  
 -1: F L E M D S L Q T D D T A M Y Y C

DNA: GCCAAACATGACGGACACGAGACTATGGACTATTGGGGTCAAGGAACCTCA  
 -1: A K H D G H E T M D Y W G Q G T S

DNA: GTCACCGTCTCCTCATCCAAACGACACCCCATCTGTCTATCCACTGGCC  
 -1: V T V S S S K T T P P S V Y P L A

DNA: CCTGGATCTGTGCCCCAACTAACTCCATGGTGACCCTGGGATGCCTGGTC  
 -1: P G S A A Q T N S M V T L G C L V

DNA: AAGGGCTATTTCCCTGAGCCAGTGACAGTGACCTGGAACCTCTGGATCCCTG  
 -1: K G Y F P E P V T V T W N S G S L

DNA: TCCAGCGGTGTGCACACCTTCCAGCTGTCTGCAGTCTGACCTCTACACT  
 -1: S S G V H T F P A V L Q S D L Y T

DNA: CTGAGCAGCTCAGTGACTGTCCCTCCAGCACCTGGCCCAGCGAGACCGTC  
 -1: L S S S V T V P S S T W P S E T V

DNA: ACCTGCAACGTTGCCCAACCGGCCAGCAGCACCAAGGTGGACAAGAAAATT  
 -1: T C N V A H P A S S T K V D K K I  
 C<sub>H</sub>1(γ1)Primer SpeI His tag Stop

DNA: GTGCCAGGGATGTACTAGTCATCATCATCATCATTAAGCTAGCCTA  
 -1: V P R D C T S H H H H H H \* A S L

DNA: GTGGTGGCGGTGGCTCTCCATTCGTTTGTGANGATAAAGGCCAATCGNAGA  
 -1: V V A V A L H S F V X I K A N R R

DNA: CCTGCNCNA  
 -1: P A X

Figure 3

4/20

A)

ATNCTTTNTTGTTCCTTTCTATGCGGCCCCAGCCGGCCATGGCCCAGGTCCAGCTG  
CAGGAGTCAGGAAGTGAAGTGGTAAAGCCTGGGGCTTCAGTGAAGTTGTCCT  
GCAAGGCTTCTGGCTACATCTTCACAAGTTATGATATAGACTGGGTGAGGCAG  
5 ACGCCTGAACAGGGACTTGAGTGGATTGGATGGATTTTTCTCTGGAGAGGGGA  
GTAAGTGAATACAATGAGAAGTTCAAGGGCAGGGCCCACTGAGTGTAGACAA  
GTCCTCCAGCACAGCCTATATGGAGCTCACTAGGCTGACATCTGAGGACTCTG  
CTGTCTATTTCTGTGCTAGAGGGGACTACTATAGGCGCTACTTTGACTTGTGGG  
GCCAAGGGGACCACGGTCACCGTCTCCTCATGTGGAGGCGGTTTCAGGCGGAGG  
10 TGGCTCTGGCGGTGGCGGATCTGACATTGAGCTCACCCAGTCTCCAGCAATCA  
TGTCTGCATCTCCAGGGGAGAGGGTCAACATGACCTGCAGTGCCAGCTC  
AAGTATACGTTACATATATTGGTACCAACAGAAGCCTGGATCCTCCCCCA  
GACTCCTGATTTATGACACATCCAACGTGGCTCCTGGAGTCCCTTTTCGC  
TTCAGTGGCAGTGGGTCTGGGACCTCTTATTCTCTCACAATCAACCGAAT  
15 GGAGGCTGAGGATGCTGCCACTTATTACTGCCAGGAGTGGAGTGGTTAT  
CCTCTCACGTTTCGGCTCGGGCACCAAGCGGGAAATCAAACGGGCGGCCGC  
AGGTGCGCCGGTGCCGTATCCGGATCCGCTGGAACCGCGTGCCGCATAGACT-  
GTTGAA

20

B)

MAQVQLQESGTEVVKPGASVKLSCKASGYIFTSYDIDWVRQTPEQGLEWIG  
WIFPGEGST EYNEKFKGRATLSVDKSSSTAYMELTRLTSEDSAVYFCARG  
25 DYRRYFDLWGQGT TVTVSSGGGSGGGGSGGGGSDIELTQSPA IMSASP  
GERVTMTCSASSSIRYIYWYQQKPGSSPRLLIYDTSNVAPGV PFRFSGSG  
SGTSYSLTINRMEAEDAATYYCQEWSGYPLTFGSGTKREIKRAAAGAPVP  
YPDPLEPR

30

35

40

Figure 4

5/20

A)

5 tcgctgccccaccagccATGgccccaggtgaaactgctcgagtcaggacctggcctggtgg  
 cgccctcagagagcctgtccatcacatgcactatctcagggttctcattaaccgacgatg  
 gtgtaagctggattcggcagcctccaggaaagggctctggagtggtgggagtaatatggg  
 gtggtggaagcacatactttaattcacttttcaaactccagactgagcatcaccagggaca  
 actctaagagccaagttttcttagaaatggacagtcacaaactgatgacacagccatgt  
 actactgcgccaacatgacggacacgagactatggactattgggggtcaaggaaacctcag  
 10 tcaccgtctcctcatccaaaacgacacccccatctgtctatccactggccctggatctg  
 ctgccccaaactaactccatggtgaccctgggatgcctggtcaagggtatattccctgagc  
 cagtga cagtgacctggaactctggatccctgtccagcgggtgtgcacacctcccagctg  
 tcctgcagtctgacctctacactctgagcagctcagtgactgtcccctccagcacctggc  
 ccagcgagaccgtcacctgcaacgttgcccaccggccagcagcaccaaggtggacaaga  
 15 aaattgtgcccagggattgtactagtggtggcggaggtagtggtggcggaggtagcggtg  
gcggaggttctggtggcggaggttccgaattcctcgaggtgcccatccaaaaagtccaag  
atgacacccaaaaccctcatcaagacaattgtcaccaggatcaatgacatttcacacacgc  
agtcagtctcctccaaacagaaagtaccgggtttggacttcattcctggggtccacccca  
tcctgaccttatccaagatggaccagacactggcagtcctaccaacagatcctcaccagta  
 20 tgccttcagaaacgtgatccaaatatccaacgacctggagaaacctccgggatcttcttc  
acgtgctggccttctctaagagctgccacttgccctgggccagtgacctggagaccttg  
acagcctgggggggtgtcctggaagcttcaggctactccacagaggtggtggcctgagca  
ggctgcaggggtctctgcaggacatgctgtggcagctggacctcagccctgggtgcacta  
gtcatcatcatcatcatcatTAAgctagcctagtgggtggcgggtggctctcca

25

B)

30 Maqvklllesgpglvapseslsitctisqfsltddgvswirqppgkglewlgviwgggsty  
fnslfksrlsitrdnsksqvflemdslqtdtdtamyycakhdghetmdywgggtsvtvsss  
ktppsvyplapgsaaqtnsmvtlgclvkgyfpepvtvtwnsgslssgvhtfpavlqsd  
yltsssvtvpssstwpsetvtcnvahpasstkvdkki vprdctsgggsgggsgggsgg  
ggseflevpigkvqddtktlikti vtrindishtqsvsskqkvtgldfipglhpiltlsk  
mdgtlavyqqiltsmprnviqisndlenlrdllhvlafskschlpwasgletldslggv  
 35 leasgystevvalsrllqgslqdmwqldlspgctshhhhhh

35

40

Figure 5

6/20




Figure 6

7/20




Figure 7

8/20




Figure 8

9/20




Figure 9

10/20




Figure 10



11/20





Figure 11

5



10


15

20

Figure 12

5

10




15

20

Figure 13

5

10



15


20

Figure 14

15/20

5

10



15


20

Figure 15

16/20

5

10



15


20

25

Figure 16

5

10



15

20


25

Figure 17

18/20

5

10



15

20

25

Figure 18



19/20






Figure 19

20/20

A)



B)



5

Figure 20

## SEQUENCE LISTING

<110> Klinikum der Universitaet Muenchen Grosshadern-Innenstadt  
 <120> Leptin antagonist and method for the quantitative measurement of leptin  
 <130> LM01P002WO  
 <150> DE 103 53 953.4  
 <151> 2003-11-17  
 <160> 8  
 <170> PatentIn version 3.1  
 <210> 1  
 <211> 272  
 <212> PRT  
 <213> Mus musculus  
 <220>  
 <221> MISC\_FEATURE  
 <222> (1)..(270)  
 <223> Xaa = unknown or other  
 <400> 1

Xaa His Asn Pro Ile Pro Met Pro Pro Ala Ala Ala Gly Leu Leu Leu  
 1 5 10 15

Leu Ala Ala Gln Pro Ala Met Ala Glu Leu Val Met Thr Gln Ser Pro  
 20 25 30

Lys Phe Met Ser Thr Ser Ile Gly Asp Arg Val Asn Ile Thr Cys Lys  
 35 40 45

Ala Thr Gln Asn Val Arg Thr Ala Val Thr Trp Tyr Gln Gln Lys Pro  
 50 55 60

Gly Gln Ser Pro Gln Ala Leu Ile Phe Leu Ala Ser Asn Arg His Thr  
 65 70 75 80

Gly Val Pro Ala Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr  
 85 90 95

Leu Thr Ile Asn Asn Val Lys Ser Glu Asp Leu Ala Asp Tyr Phe Cys  
 100 105 110

Leu Gln His Trp Asn Tyr Pro Leu Thr Phe Gly Ser Gly Thr Lys Leu  
 115 120 125

Glu Ile Lys Arg Ala Asp Ala Ala Pro Thr Val Ser Ile Phe Pro Pro  
 130 135 140

Ser Ser Glu Gln Leu Thr Ser Gly Gly Ala Ser Val Val Cys Phe Leu  
 145 150 155 160

Asn Asn Phe Tyr Pro Lys Asp Ile Asn Val Lys Trp Lys Ile Asp Gly  
 165 170 175

Ser Glu Arg Gln Asn Gly Val Leu Asn Ser Trp Thr Asp Gln Asp Ser  
 180 185 190

Lys Asp Ser Thr Tyr Ser Met Ser Ser Thr Leu Thr Leu Thr Lys Asp  
 195 200 205

Glu Tyr Glu Arg His Asn Ser Tyr Thr Cys Glu Ala Thr His Lys Thr  
 210 215 220

Ser Thr Ser Pro Ile Val Lys Ser Phe Asn Arg Gly Glu Cys Xaa Xaa  
 225 230 235 240

Ser Arg Val Lys Arg Xaa Gln Ser Xaa Gly Gly Pro Gly Thr Pro Ile  
 245 250 255

Arg Pro Ile Gly Xaa Pro Tyr Tyr Asn Ser Leu Gly Gly Gly Phe Gln  
 260 265 270

<210> 2  
 <211> 818  
 <212> DNA  
 <213> Mus musculus

<220>  
 <221> misc\_feature  
 <222> (1)..(818)  
 <223> n = a, t, g, c, unknown or other

<220>  
 <221> CDS  
 <222> (3)..(818)  
 <223>

<400> 2  
 na ngt cat aat cca ata cct atg cct acg gca gcc gct gga ttg tta 47  
 Xaa His Asn Pro Ile Pro Met Pro Thr Ala Ala Ala Gly Leu Leu  
 1 5 10 15

tta ctc gct gcc caa cca gcc atg gcc gag ctc gtg atg acc cag tct 95  
 Leu Leu Ala Ala Gln Pro Ala Met Ala Glu Leu Val Met Thr Gln Ser  
 20 25 30

cca aaa ttc atg tcc aca tca ata gga gac agg gtc aat atc acc tgc 143  
 Pro Lys Phe Met Ser Thr Ser Ile Gly Asp Arg Val Asn Ile Thr Cys  
 35 40 45

3/12

aag gcc act cag aat gtt cgt act gct gtt acc tgg tat caa cag aaa	191
Lys Ala Thr Gln Asn Val Arg Thr Ala Val Thr Trp Tyr Gln Gln Lys	
50 55 60	
cca ggg cag tct cct caa gca ctg att ttc ttg gca tcc aac cgg cac	239
Pro Gly Gln Ser Pro Gln Ala Leu Ile Phe Leu Ala Ser Asn Arg His	
65 70 75	
act ggt gtc cct gct cga ttc aca ggc agt gga tct ggg aca gat ttc	287
Thr Gly Val Pro Ala Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe	
80 85 90 95	
act ctc acc att aac aat gtg aaa tct gaa gac ctg gca gat tat ttc	335
Thr Leu Thr Ile Asn Asn Val Lys Ser Glu Asp Leu Ala Asp Tyr Phe	
100 105 110	
tgt cta caa cat tgg aat tat cct ctc acg ttc ggc tcg ggg aca aag	383
Cys Leu Gln His Trp Asn Tyr Pro Leu Thr Phe Gly Ser Gly Thr Lys	
115 120 125	
ttg gaa ata aaa cgg gct gat gct gca cca act gta tcc atc ttc cca	431
Leu Glu Ile Lys Arg Ala Asp Ala Ala Pro Thr Val Ser Ile Phe Pro	
130 135 140	
cca tcc agt gag cag tta aca tct gga ggt gcc tca gtc gtg tgc ttc	479
Pro Ser Ser Glu Gln Leu Thr Ser Gly Gly Ala Ser Val Val Cys Phe	
145 150 155	
ttg aac aac ttc tac ccc aaa gac atc aat gtc aag tgg aag att gat	527
Leu Asn Asn Phe Tyr Pro Lys Asp Ile Asn Val Lys Trp Lys Ile Asp	
160 165 170 175	
ggc agt gaa cga caa aat ggc gtc ctg aac agt tgg act gat cag gac	575
Gly Ser Glu Arg Gln Asn Gly Val Leu Asn Ser Trp Thr Asp Gln Asp	
180 185 190	
agc aaa gac agc acc tac agc atg agc agc acc ctc acg ttg acc aag	623
Ser Lys Asp Ser Thr Tyr Ser Met Ser Ser Thr Leu Thr Leu Thr Lys	
195 200 205	
gac gag tat gaa cga cat aac agc tat acc tgt gag gcc act cac aag	671
Asp Glu Tyr Glu Arg His Asn Ser Tyr Thr Cys Glu Ala Thr His Lys	
210 215 220	
aca tca act tca ccc att gtc aag agc ttc aac agg gga gag tgt tag	719
Thr Ser Thr Ser Pro Ile Val Lys Ser Phe Asn Arg Gly Glu Cys	
225 230 235	
taa tct aga gtt aag cgg ccg caa tcg agg ggg ggc ccg gta ccc caa	767
Ser Arg Val Lys Arg Pro Gln Ser Arg Gly Gly Pro Val Pro Gln	
240 245 250	
ttc gcc cta tag ggg ngc cgt att aca att cac tgg gcg gcg gtt ttc	815
Phe Ala Leu Gly Xaa Arg Ile Thr Ile His Trp Ala Ala Val Phe	
255 260 265	
aan	818
Xaa	

&lt;210&gt; 3

&lt;211&gt; 292

<212> PRT  
 <213> Mus musculus

<220>  
 <221> MISC FEATURE  
 <222> (1)..(292)  
 <223> Xaa = any or other

<400> 3

Leu Ala Xaa Arg Gly Gly Gly Arg Lys Ile Xaa Phe Xaa Arg Glu Thr  
 1 5 10 15

Val Ile Met Lys Tyr Leu Xaa Ala Tyr Gly Pro Ala Ala Gly Leu Leu  
 20 25 30

Leu Leu Ala Ala Gln Pro Ala Met Ala Gln Val Lys Leu Leu Glu Ser  
 35 40 45

Gly Pro Gly Leu Val Ala Pro Ser Glu Ser Leu Ser Ile Thr Cys Thr  
 50 55 60

Ile Ser Gly Phe Ser Leu Thr Asp Asp Gly Val Ser Trp Ile Arg Gln  
 65 70 75 80

Pro Pro Gly Lys Gly Leu Glu Trp Leu Gly Val Ile Trp Gly Gly Gly  
 85 90 95

Ser Thr Tyr Phe Asn Ser Leu Phe Lys Ser Arg Leu Ser Ile Thr Arg  
 100 105 110

Asp Asn Ser Lys Ser Gln Val Phe Leu Glu Met Asp Ser Leu Gln Thr  
 115 120 125

Asp Asp Thr Ala Met Tyr Tyr Cys Ala Lys His Asp Gly His Glu Thr  
 130 135 140

Met Asp Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser Ser Lys  
 145 150 155 160

Thr Thr Pro Pro Ser Val Tyr Pro Leu Ala Pro Gly Ser Ala Ala Gln  
 165 170 175

Thr Asn Ser Met Val Thr Leu Gly Cys Leu Val Lys Gly Tyr Phe Pro  
 180 185 190

Glu Pro Val Thr Val Thr Trp Asn Ser Gly Ser Leu Ser Ser Gly Val  
 195 200 205

5/12

His Thr Phe Pro Ala Val Leu Gln Ser Asp Leu Tyr Thr Leu Ser Ser  
 210 215 220

Ser Val Thr Val Pro Ser Ser Thr Trp Pro Ser Glu Thr Val Thr Cys  
 225 230 235 240

Asn Val Ala His Pro Ala Ser Ser Thr Lys Val Asp Lys Lys Ile Val  
 245 250 255

Pro Arg Asp Cys Thr Ser His His His His His Xaa Ala Ser Leu  
 260 265 270

Val Val Ala Val Ala Leu His Ser Phe Val Xaa Ile Lys Ala Asn Arg  
 275 280 285

Arg Pro Ala Xaa  
 290

<210> 4  
 <211> 876  
 <212> DNA  
 <213> Mus musculus

<220>  
 <221> misc\_feature  
 <222> (1)..(876)  
 <223> n = a, t, g, c, unknown or other

<220>  
 <221> CDS  
 <222> (1)..(876)  
 <223>

<400> 4  
 ttg gcc ncc cgc ggt ggc ggc cgc aaa att nta ttt nca agg gag aca 48  
 Leu Ala Xaa Arg Gly Gly Gly Arg Lys Ile Xaa Phe Xaa Arg Glu Thr  
 1 5 10 15  
 gtc ata atg aaa tac ctt ttn gcc tac ggg cca gcc gct gga ttg tta 96  
 Val Ile Met Lys Tyr Leu Xaa Ala Tyr Gly Pro Ala Ala Gly Leu Leu  
 20 25 30  
 tta ctc gct gcc caa cca gcc atg gcc cag gtg aaa ctg ctc gag tca 144  
 Leu Leu Ala Ala Gln Pro Ala Met Ala Gln Val Lys Leu Leu Glu Ser  
 35 40 45  
 gga cct ggc ctg gtg gcg ccc tca gag agc ctg tcc atc aca tgc act 192  
 Gly Pro Gly Leu Val Ala Pro Ser Glu Ser Leu Ser Ile Thr Cys Thr  
 50 55 60  
 atc tca ggg ttc tca tta acc gac gat ggt gta agc tgg att cgg cag 240  
 Ile Ser Gly Phe Ser Leu Thr Asp Asp Gly Val Ser Trp Ile Arg Gln  
 65 70 75 80  
 cct cca gga aag ggt ctg gag tgg ctg gga gta ata tgg ggt ggt gga 288

6/12

Pro	Pro	Gly	Lys	Gly	Leu	Glu	Trp	Leu	Gly	Val	Ile	Trp	Gly	Gly	Gly		
				85					90					95			
agc	aca	tac	ttt	aat	tca	ctt	ttc	aaa	tcc	aga	ctg	agc	atc	acc	agg	336	
Ser	Thr	Tyr	Phe	Asn	Ser	Leu	Phe	Lys	Ser	Arg	Leu	Ser	Ile	Thr	Arg		
			100					105					110				
gac	aac	tct	aag	agc	caa	gtt	ttc	tta	gaa	atg	gac	agt	cta	caa	act	384	
Asp	Asn	Ser	Lys	Ser	Gln	Val	Phe	Leu	Glu	Met	Asp	Ser	Leu	Gln	Thr		
			115				120					125					
gat	gac	aca	gcc	atg	tac	tac	tgc	gcc	aaa	cat	gac	gga	cac	gag	act	432	
Asp	Asp	Thr	Ala	Met	Tyr	Tyr	Cys	Ala	Lys	His	Asp	Gly	His	Glu	Thr		
			130				135					140					
atg	gac	tat	tgg	ggt	caa	gga	acc	tca	gtc	acc	gtc	tcc	tca	tcc	aaa	480	
Met	Asp	Tyr	Trp	Gly	Gln	Gly	Thr	Ser	Val	Thr	Val	Ser	Ser	Ser	Lys		
					150					155					160		
acg	aca	ccc	cca	tct	gtc	tat	cca	ctg	gcc	cct	gga	tct	gct	gcc	caa	528	
Thr	Thr	Pro	Pro	Ser	Val	Tyr	Pro	Leu	Ala	Pro	Gly	Ser	Ala	Ala	Gln		
				165					170					175			
act	aac	tcc	atg	gtg	acc	ctg	gga	tgc	ctg	gtc	aag	ggc	tat	ttc	cct	576	
Thr	Asn	Ser	Met	Val	Thr	Leu	Gly	Cys	Leu	Val	Lys	Gly	Tyr	Phe	Pro		
			180					185					190				
gag	cca	gtg	aca	gtg	acc	tgg	aac	tct	gga	tcc	ctg	tcc	agc	ggt	gtg	624	
Glu	Pro	Val	Thr	Val	Thr	Trp	Asn	Ser	Gly	Ser	Leu	Ser	Ser	Gly	Val		
			195				200					205					
cac	acc	ttc	cca	gct	gtc	ctg	cag	tct	gac	ctc	tac	act	ctg	agc	agc	672	
His	Thr	Phe	Pro	Ala	Val	Leu	Gln	Ser	Asp	Leu	Tyr	Thr	Leu	Ser	Ser		
			210				215					220					
tca	gtg	act	gtc	ccc	tcc	agc	acc	tgg	ccc	agc	gag	acc	gtc	acc	tgc	720	
Ser	Val	Thr	Val	Pro	Ser	Ser	Thr	Trp	Pro	Ser	Glu	Thr	Val	Thr	Cys		
					230					235					240		
aac	gtt	gcc	cac	ccg	gcc	agc	agc	acc	aag	gtg	gac	aag	aaa	att	gtg	768	
Asn	Val	Ala	His	Pro	Ala	Ser	Ser	Thr	Lys	Val	Asp	Lys	Lys	Ile	Val		
				245					250					255			
ccc	agg	gat	tgt	act	agt	cat	cat	cat	cat	cat	cat	taa	gct	agc	cta	816	
Pro	Arg	Asp	Cys	Thr	Ser	His	His	His	His	His	His		Ala	Ser	Leu		
			260					265						270			
gtg	gtg	gcg	gtg	gct	ctc	cat	tcg	ttt	gtg	ang	ata	aag	gcc	aat	cgn	864	
Val	Val	Ala	Val	Ala	Leu	His	Ser	Phe	Val	Xaa	Ile	Lys	Ala	Asn	Arg		
			275					280					285				
aga	cct	gcn	cna													876	
Arg	Pro	Ala	Xaa														
			290														

<210> 5  
 <211> 832  
 <212> DNA  
 <213> Mus musculus

<220>  
 <221> misc\_feature



&lt;222&gt; (1)..(832)

&lt;223&gt; n = a, t, g, c, any or other

&lt;220&gt;

&lt;221&gt; CDS

&lt;222&gt; (38)..(814)

&lt;223&gt;

&lt;400&gt; 5

atnctttntt gttcctttct atgcggccca gccggcc atg gcc cag gtc cag ctg 55  
 Met Ala Gln Val Gln Leu  
 1 5

cag gag tca gga act gaa gtg gta aag cct ggg gct tca gtg aag ttg 103  
 Gln Glu Ser Gly Thr Glu Val Val Lys Pro Gly Ala Ser Val Lys Leu  
 10 15 20

tcc tgc aag gct tct ggc tac atc ttc aca agt tat gat ata gac tgg 151  
 Ser Cys Lys Ala Ser Gly Tyr Ile Phe Thr Ser Tyr Asp Ile Asp Trp  
 25 30 35

gtg agg cag acg cct gaa cag gga ctt gag tgg att gga tgg att ttt 199  
 Val Arg Gln Thr Pro Glu Gln Gly Leu Glu Trp Ile Gly Trp Ile Phe  
 40 45 50

cct gga gag ggg agt act gaa tac aat gag aag ttc aag ggc agg gcc 247  
 Pro Gly Glu Gly Ser Thr Glu Tyr Asn Glu Lys Phe Lys Gly Arg Ala  
 55 60 65 70

aca ctg agt gta gac aag tcc tcc agc aca gcc tat atg gag ctc act 295  
 Thr Leu Ser Val Asp Lys Ser Ser Ser Thr Ala Tyr Met Glu Leu Thr  
 75 80 85

agg ctg aca tct gag gac tct gct gtc tat ttc tgt gct aga ggg gac 343  
 Arg Leu Thr Ser Glu Asp Ser Ala Val Tyr Phe Cys Ala Arg Gly Asp  
 90 95 100

tac tat agg cgc tac ttt gac ttg tgg ggc caa ggg acc acg gtc acc 391  
 Tyr Tyr Arg Arg Tyr Phe Asp Leu Trp Gly Gln Gly Thr Thr Val Thr  
 105 110 115

gtc tcc tca tgt gga ggc ggt tca ggc gga ggt ggc tct ggc ggt ggc 439  
 Val Ser Ser Cys Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly  
 120 125 130

gga tct gac att gag ctc acc cag tct cca gca atc atg tct gca tct 487  
 Gly Ser Asp Ile Glu Leu Thr Gln Ser Pro Ala Ile Met Ser Ala Ser  
 135 140 145 150

cca ggg gag agg gtc acc atg acc tgc agt gcc agc tca agt ata cgt 535  
 Pro Gly Glu Arg Val Thr Met Thr Cys Ser Ala Ser Ser Ser Ile Arg  
 155 160 165

tac ata tat tgg tac caa cag aag cct gga tcc tcc ccc aga ctc ctg 583  
 Tyr Ile Tyr Trp Tyr Gln Gln Lys Pro Gly Ser Ser Pro Arg Leu Leu  
 170 175 180

att tat gac aca tcc aac gtg gct cct gga gtc cct ttt cgc ttc agt 631  
 Ile Tyr Asp Thr Ser Asn Val Ala Pro Gly Val Pro Phe Arg Phe Ser  
 185 190 195

8/12

ggc agt ggg tct ggg acc tct tat tct ctc aca atc aac cga atg gag 679  
 Gly Ser Gly Ser Gly Thr Ser Tyr Ser Leu Thr Ile Asn Arg Met Glu  
 200 205 210

gct gag gat gct gcc act tat tac tgc cag gag tgg agt ggt tat cct 727  
 Ala Glu Asp Ala Ala Thr Tyr Tyr Cys Gln Glu Trp Ser Gly Tyr Pro  
 215 220 225 230

ctc acg ttc ggc tgc ggc acc aag cgg gaa atc aaa cgg gcg gcc gca 775  
 Leu Thr Phe Gly Ser Gly Thr Lys Arg Glu Ile Lys Arg Ala Ala Ala  
 235 240 245

ggt gcg ccg gtg ccg tat ccg gat ccg ctg gaa ccg cgt gccgcataga 824  
 Gly Ala Pro Val Pro Tyr Pro Asp Pro Leu Glu Pro Arg  
 250 255

ctgttgaa 832

<210> 6  
 <211> 259  
 <212> PRT  
 <213> Mus musculus

<220>  
 <221> misc\_feature  
 <222> (1)..(832)  
 <223> n = a, t, g, c, any or other

<400> 6

Met Ala Gln Val Gln Leu Gln Glu Ser Gly Thr Glu Val Val Lys Pro  
 1 5 10 15

Gly Ala Ser Val Lys Leu Ser Cys Lys Ala Ser Gly Tyr Ile Phe Thr  
 20 25 30

Ser Tyr Asp Ile Asp Trp Val Arg Gln Thr Pro Glu Gln Gly Leu Glu  
 35 40 45

Trp Ile Gly Trp Ile Phe Pro Gly Glu Gly Ser Thr Glu Tyr Asn Glu  
 50 55 60

Lys Phe Lys Gly Arg Ala Thr Leu Ser Val Asp Lys Ser Ser Ser Thr  
 65 70 75 80

Ala Tyr Met Glu Leu Thr Arg Leu Thr Ser Glu Asp Ser Ala Val Tyr  
 85 90 95

Phe Cys Ala Arg Gly Asp Tyr Tyr Arg Arg Tyr Phe Asp Leu Trp Gly  
 100 105 110

Gln Gly Thr Thr Val Thr Val Ser Ser Cys Gly Gly Gly Ser Gly Gly  
 115 120 125

9/12

Gly Gly Ser Gly Gly Gly Gly Ser Asp Ile Glu Leu Thr Gln Ser Pro  
 130 135 140

Ala Ile Met Ser Ala Ser Pro Gly Glu Arg Val Thr Met Thr Cys Ser  
 145 150 155 160

Ala Ser Ser Ser Ile Arg Tyr Ile Tyr Trp Tyr Gln Gln Lys Pro Gly  
 165 170 175

Ser Ser Pro Arg Leu Leu Ile Tyr Asp Thr Ser Asn Val Ala Pro Gly  
 180 185 190

Val Pro Phe Arg Phe Ser Gly Ser Gly Ser Gly Thr Ser Tyr Ser Leu  
 195 200 205

Thr Ile Asn Arg Met Glu Ala Glu Asp Ala Ala Thr Tyr Tyr Cys Gln  
 210 215 220

Glu Trp Ser Gly Tyr Pro Leu Thr Phe Gly Ser Gly Thr Lys Arg Glu  
 225 230 235 240

Ile Lys Arg Ala Ala Ala Gly Ala Pro Val Pro Tyr Pro Asp Pro Leu  
 245 250 255

Glu Pro Arg

<210> 7  
 <211> 1252  
 <212> DNA  
 <213> Mus musculus

<220>  
 <221> misc\_feature  
 <222> (1)..(1252)  
 <223> n = a, t, g, c, unknown or other

<400> 7  
 tcgctgccca accagccatg gccaggtga aactgctoga gtcaggacct ggcttgggtg 60  
 cgccctcaga gagcctgtcc atcacatgca ctatctcagg gttctcatta accgacgatg 120  
 gtgtaagctg gattcggcag cctccaggaa agggctctgga gtggctggga gtaatatggg 180  
 gtgggtggaag cacatacttt aattcacttt tcaaatoag actgagcatc accagggaca 240  
 actctaagag ccaagttttc ttagaaatgg acagtctaca aactgatgac acagccatgt 300  
 actactgctc caaacatgac ggacacgaga ctatggacta ttgggggtcaa ggaacctcag 360  
 tcaccgtctc ctcatccaaa acgacacccc catctgtcta tccactggcc cctggatctg 420  
 ctgcccacaaac taactccatg gtgaccctgg gatgcctggg caagggctat ttccctgagc 480

```

cagtgacagt gacctggaac tctggatccc tgtccagcgg tgtgcacacc ttcccagctg      540
tcctgcagtc tgacctctac actctgagca gctcagtgac tgtcccctcc agcacctggc      600
ccagcgagac cgtcacctgc aacgttgccc acccggccag cagcaccaag gtggacaaga      660
aaattgtgcc cagggattgt actagtgggtg gcggaggtag tggtggcgga ggtagcggtg      720
gcggaggttc tggtggcgga ggttcggaat tcctcgaggt gcccatccaa aaagtccaag      780
atgacaccaa aaccctcatc aagacaattg tcaccaggat caatgacatt tcacacacgc      840
agtcagtctc ctcaaacag aaagtcaccg gtttggactt cattcctggg ctccacccca      900
tcctgacctt atccaagatg gaccagacac tggcagtcta ccaacagatc ctcaccagta      960
tgccctccag aaacgtgatc caaatatcca acgacctgga gaacctccgg gatcttcttc     1020
acgtgctggc cttctctaag agctgccact tgccctgggc cagtggcctg gagaccttgg     1080
acagcctggg ggggtgtcctg gaagcttcag gctactccac agaggtgggtg gccctgagca     1140
ggctgcaggg gtctctgcag gacatgctgt ggcagctgga cctcagccct ggggtgcacta     1200
gtcatcatca tcatcatcat taagctagcc tagtggtggc ggtggctctc ca              1252

```

&lt;210&gt; 8

&lt;211&gt; 401

&lt;212&gt; PRT

&lt;213&gt; Mus musculus

&lt;220&gt;

&lt;221&gt; MISC\_FEATURE

&lt;222&gt; (1)..(401)

&lt;223&gt; Xaa = unknown or other

&lt;400&gt; 8

```

Met Ala Gln Val Lys Leu Leu Glu Ser Gly Pro Gly Leu Val Ala Pro
1           5           10          15

```

```

Ser Glu Ser Leu Ser Ile Thr Cys Thr Ile Ser Gly Phe Ser Leu Thr
          20           25          30

```

```

Asp Asp Gly Val Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu
          35           40          45

```

```

Trp Leu Gly Val Ile Trp Gly Gly Gly Ser Thr Tyr Phe Asn Ser Leu
          50           55          60

```

```

Phe Lys Ser Arg Leu Ser Ile Thr Arg Asp Asn Ser Lys Ser Gln Val
65           70           75          80

```

```

Phe Leu Glu Met Asp Ser Leu Gln Thr Asp Asp Thr Ala Met Tyr Tyr
          85           90          95

```

Cys Ala Lys His Asp Gly His Glu Thr Met Asp Tyr Trp Gly Gln Gly  
 100 105 110

Thr Ser Val Thr Val Ser Ser Ser Lys Thr Thr Pro Pro Ser Val Tyr  
 115 120 125

Pro Leu Ala Pro Gly Ser Ala Ala Gln Thr Asn Ser Met Val Thr Leu  
 130 135 140

Gly Cys Leu Val Lys Gly Tyr Phe Pro Glu Pro Val Thr Val Thr Trp  
 145 150 155 160

Asn Ser Gly Ser Leu Ser Ser Gly Val His Thr Phe Pro Ala Val Leu  
 165 170 175

Gln Ser Asp Leu Tyr Thr Leu Ser Ser Ser Val Thr Val Pro Ser Ser  
 180 185 190

Thr Trp Pro Ser Glu Thr Val Thr Cys Asn Val Ala His Pro Ala Ser  
 195 200 205

Ser Thr Lys Val Asp Lys Lys Ile Val Pro Arg Asp Cys Thr Ser Gly  
 210 215 220

Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly  
 225 230 235 240

Gly Gly Ser Glu Phe Leu Glu Val Pro Ile Gln Lys Val Gln Asp Asp  
 245 250 255

Thr Lys Thr Leu Ile Lys Thr Ile Val Thr Arg Ile Asn Asp Ile Ser  
 260 265 270

His Thr Gln Ser Val Ser Ser Lys Gln Lys Val Thr Gly Leu Asp Phe  
 275 280 285

Ile Pro Gly Leu His Pro Ile Leu Thr Leu Ser Lys Met Asp Gln Thr  
 290 295 300

Leu Ala Val Tyr Gln Gln Ile Leu Thr Ser Met Pro Ser Arg Asn Val  
 305 310 315 320

Ile Gln Ile Ser Asn Asp Leu Glu Asn Leu Arg Asp Leu Leu His Val  
 325 330 335

Leu Ala Phe Ser Lys Ser Cys His Leu Pro Trp Ala Ser Gly Leu Glu

340

345

350

Thr Leu Asp Ser Leu Gly Gly Val Leu Glu Ala Ser Gly Tyr Ser Thr  
355 360 365

Glu Val Val Ala Leu Ser Arg Leu Gln Gly Ser Leu Gln Asp Met Leu  
370 375 380

Trp Gln Leu Asp Leu Ser Pro Gly Cys Thr Ser His His His His His  
385 390 395 400

His

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07K16/28 G01N33/74 G01N33/53

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, BIOSIS, EMBASE, PAJ, WPI Data, EMBL

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>WU ZIDA ET AL: "Quantification of the soluble leptin receptor in human blood by ligand-mediated immunofunctional assay" JOURNAL OF CLINICAL ENDOCRINOLOGY AND METABOLISM, vol. 87, no. 6, June 2002 (2002-06), pages 2931-2939, XP002323286 ISSN: 0021-972X abstract page 2932, right-hand column, paragraph 2 - page 2933, right-hand column, last paragraph figure 2</p> <p style="text-align: center;">----- -/--</p>	1-21, 33-35, 40-42

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

## \* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

Date of the actual completion of the international search

5 April 2005

Date of mailing of the international search report

19/04/2005

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Ulbrecht, M

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>MAINGRETTE FRITZ ET AL: "Leptin increases lipoprotein lipase secretion by macrophages: Involvement of oxidative stress and protein kinase C."  DIABETES,  vol. 52, no. 8, August 2003 (2003-08),  pages 2121-2128, XP002323287  ISSN: 0012-1797  abstract  page 2121, right-hand column, last paragraph - page 2122, left-hand column, paragraph 1  page 2123, right-hand column, paragraph 3  figure 3</p>	<p>1-21,  33-35,  40-42</p>
X	<p>CORSONELLO A ET AL: "Leptin-dependent platelet aggregation in healthy, overweight and obese subjects."  INTERNATIONAL JOURNAL OF OBESITY,  vol. 27, no. 5, May 2003 (2003-05), pages 566-573, XP002323288  ISSN: 0307-0565  abstract  page 567, right-hand column, paragraph 5  page 569, left-hand column, paragraph 2  figure 4</p>	<p>1-21,  33-35,  40-42</p>
X	<p>IVERSEN PER OLE ET AL: "Prevention of leptin binding to its receptor suppresses rat leukemic cell growth by inhibiting angiogenesis."  BLOOD,  vol. 100, no. 12,  1 December 2002 (2002-12-01), pages 4123-4128, XP002323289  ISSN: 0006-4971  abstract  page 4124, left-hand column, paragraph 3  figure 2</p>	<p>1-21,  33-35,  40-42</p>
X	<p>WO 99/59614 A (YALE UNIVERSITY;  SIERRA-HONIGMANN, ROCIO, M)  25 November 1999 (1999-11-25)  page 24, line 12 - line 18  example 1</p>	<p>1-21,  33-35,  40-42</p>
X	<p>WO 00/76552 A (BAYLOR COLLEGE OF MEDICINE)  21 December 2000 (2000-12-21)  page 27, line 6 - line 7</p>	<p>1-21,  33-35,  40-42</p>



**Box II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)**

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 42  
because they relate to subject matter not required to be searched by this Authority, namely:  
Although claim 42 is directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

**Box III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)**

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

Patent document cited in search report		Publication date	Patent family member(s)		Publication date
WO 9959614	A	25-11-1999	AU	4672199 A	06-12-1999
			WO	9959614 A1	25-11-1999
WO 0076552	A	21-12-2000	AU	767068 B2	30-10-2003
			AU	5603100 A	02-01-2001
			CA	2376933 A1	21-12-2000
			EP	1191945 A1	03-04-2002
			JP	2003528804 T	30-09-2003
			WO	0076552 A1	21-12-2000
			US	2004202652 A1	14-10-2004

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**